James Tisdale CV - Purdue University · CURRICULUM VITAE James Edward Tisdale Business Address:...

James E. Tisdale, PharmD

1

CURRICULUM VITAE

James Edward Tisdale Business Address: Department of Pharmacy Practice College of Pharmacy Purdue University 640 Eskenazi Avenue Indianapolis, IN 46202

Home Address: 13787 Hickory Ridge Court

Carmel, Indiana 46032

Telephone: (317) 880-5418 (317) 880-0568 (fax) (317) 844-2073 (home) Email: [email protected]

Place of Birth: Winnipeg, Manitoba, Canada

Citizenship Status: United States citizen Canadian citizen Education: July, 1988 - June, 1990 Fellowship, Cardiovascular Therapeutics

Hartford Hospital, Hartford, Connecticut Mentor: Moses S.S. Chow, PharmD, FCCP, FCP

June, 1988 Doctor of Pharmacy

State University of New York at Buffalo Buffalo, New York

June, 1983 - June, 1984 Pharmacy Practice Residency

Health Sciences Centre Winnipeg, Manitoba, Canada

May, 1983 Bachelor of Science in Pharmacy

University of Manitoba Winnipeg, Manitoba, Canada


2

Additional Training: October, 2002 – January, 2003 Mini-sabbatical College of Pharmacy Ohio State University Preceptor: Cynthia Carnes, PharmD, PhD Total duration: 4 weeks Learned techniques in animal surgery, AV nodal ablation, pacemaker implantation, isolated perfused heart model, myocyte isolation, and voltage clamping for determination of cellular ion movement Academic Appointments: February 1, 2012 – Interim Head August 31, 2014 Department of Pharmacy Practice College of Pharmacy Purdue University Indianapolis, Indiana July, 2005 – present Professor

Department of Pharmacy Practice College of Pharmacy

Purdue University Indianapolis, Indiana

December, 2005 – present Adjunct Professor Division of Clinical Pharmacology School of Medicine Indiana University Indianapolis, IN

December, 2002 – present Adjunct Associate Professor

Division of Clinical Pharmacology School of Medicine Indiana University Indianapolis, IN

August, 2002 – July, 2005 Associate Professor

Department of Pharmacy Practice College of Pharmacy


3

Academic Appointments (cont’d): Purdue University Indianapolis, Indiana

August, 1996 – July, 2002 Associate Professor College of Pharmacy and Health Sciences Wayne State University Detroit, Michigan

August, 1990 – July, 1996 Assistant Professor

College of Pharmacy and Allied Health Professions Wayne State University

Detroit, Michigan October, 1988 - June, 1990 Adjunct Clinical Instructor

Massachusetts College of Pharmacy and Allied Health Sciences (Western New England College Campus) Springfield, MA

July, 1988 – June, 1990 Assistant Clinical Professor School of Pharmacy University of Connecticut Storrs, CT

January, 1987 - May, 1987 Graduate Teaching Assistant

Professional Practice Laboratory - School of Pharmacy State University of New York at Buffalo Buffalo, New York

Professional Experience: August, 1990 – July, 2002 Coordinator, Education and Training

Department of Pharmacy Services Henry Ford Hospital Detroit, Michigan

September, 1984 - Pharmacist June, 1986 Adult Critical Care Satellite Pharmacy Health Sciences Centre

Winnipeg, Manitoba, Canada


4

Professional Experience (cont’d): June, 1984 – September, 1984 Pharmacist

Central Pharmacy Health Sciences Centre Winnipeg, Manitoba, Canada

Registration and Licensing: Pharmacy Examining Board of Canada #8424 Michigan license # 5302028422

Indiana license # 26021035A Certification/Additional Specialized Training 1990 – 2002, 2011-present Basic Life Support (BLS) Provider

1990 – 2002, 2011- present Advanced Cardiac Life Support (ACLS) Provider

1992 Board Certified Pharmacotherapy Specialist (BCPS) 1999 Recertified as a Board Certified Pharmacotherapy Specialist (BCPS)

1997, 1998, 1999 American Heart Association-approved ACLS Instructor 2000 Added Qualifications in Cardiology Pharmacotherapy,

credentialed by the Board of Pharmacy Specialties (BPS)

2006 Recertified as a Board Certified Pharmacotherapy Specialist (BCPS)

2008 Renewed Added Qualifications in Cardiology

Pharmacotherapy, credentialed by the Board of Pharmacy Specialties (BPS)

2013 Recertified as a Board Certified Pharmacotherapy

Specialist (BCPS)


5

Certification/Additional Specialized Training (cont’d): 2015 Renewed Added Qualifications in Cardiology

Pharmacotherapy, credentialed by BPS

Publications Journal Articles: 1. Tisdale JE. Justifying a pediatric critical care satellite pharmacy by medication error

reporting. Am J Hosp Pharm 1986;43:368-371.

2. Tisdale J. Epidural fentanyl for pain control. Can J Hosp Pharm 1986;39:170. 3. Tisdale J. Therapy of peptic ulcer disease. Can J Hosp Pharm 1987;40:12-22.

4. Tisdale JE. Combination antiarrhythmic therapy. Connecticut Medicine

1989;53:101-105.

5. Tisdale JE, Pasko MT, Mylotte JM. Antipseudomonal activity of simulated infusions of gentamicin alone or with piperacillin assessed by serum bactericidal rate and area under the killing curve. Antimicrob Agents Chemother 1989;33:1500-1505.

6. Tisdale JE, Chow MSS. Focus on sotalol: an adrenergic β-receptor blocking agent with class III antiarrhythmic activity. Hosp Formul 1989;24:485-497.

7. Tisdale JE, Stringer KA Antalek M, Matthews GE. Streptokinase-induced anaphylaxis. Ann Pharmacother 1989;23:984-986. 8. Tisdale JE, Chow MSS. Dilevalol: Mechanism of action, effectiveness and safety. IM. Internal Medicine for the Specialist 1990;11:63-74. 9. Tisdale JE, Kambe JC, Chow MSS, Yeston NS. The effect of haloperidol on ventricular

fibrillation threshold in pigs. Pharmacol Toxicol 1991;69:327-329.

10. Tisdale JE. Lidocaine prophylaxis in acute myocardial infarction. Henry Ford Hosp Med J 1991;39:217-225.

11. Tisdale JE, Gheorghiade M. Acute hemodynamic effects of digoxin alone or in

combination with other vasoactive agents in patients with heart failure. Am J Cardiol 1992;69:34G-47G.


6

Journal Articles (cont'd): 12. Tisdale JE, Webb CR. Are antiarrhythmic drugs obsolete? Clin Pharm 1992;11:714-726. 13. Tisdale JE, Tsuyuki RT, Oles KS, Penry JK. Relationship between serum concentration and dose of valproic acid during monotherapy in adult outpatients. Ther Drug Monit 1992;14:416-423. 14. Tisdale JE, Colucci RD, Ujhelyi MR, Kluger J, Fieldman A, Chow MSS. Evaluation

and comparison of the adverse effects of streptokinase and alteplase. Pharmacotherapy 1992;12:440-444.

15. Tisdale JE, Kluger J, Fisher JR, Chow MSS. Efficacy of class 1C antiarrhythmic agents in patients with inducible ventricular tachycardia refractory to class 1A antiarrhythmic drugs. J Clin Pharmacol 1993;33:623-630. 16. Fan C, Tisdale JE, Ujhelyi MR, Chow MSS. Accuracy of unbound-quinidine concentration determination after ultrafiltration. Clin Pharm 1993;12:917-921. 17. Tisdale JE, Patel R, Borzak S, Webb CR, Zarowitz BJ. Proarrhythmic effects of

intravenous vasopressors. Ann Pharmacother 1995;29:269-281. 18. Tisdale JE, Follin SL, Ordelova A, Webb CR. Risk factors for the development of specific noncardiovascular adverse effects associated with amiodarone. J Clin Pharmacol 1995; 35:351-356. 19. Tisdale JE, Patel R, Borzak S, Webb CR, Zarowitz BJ. Electrophysiologic and

proarrhythmic effects of intravenous inotropic agents. Prog Cardiovasc Dis 1995;38:167-180.

20. Tisdale JE, Rudis MI, Padhi ID, Svensson CK, Webb CR, Borzak S, Ware JA,

Krepostman A, Zarowitz BJ. Inhibition of N-acetylation of procainamide and renal clearance of N-acetylprocainamide by para-aminobenzoic acid in humans. J Clin Pharmacol 1995;35:902-910.

21. Tisdale JE, Rudis MI, Padhi ID, Borzak S, Svensson CK, Webb CR, Acciaioli J, Ware

JA, Krepostman A, Zarowitz BJ. Disposition of procainamide in patients with chronic congestive heart failure receiving medical therapy. J Clin Pharmacol 1996;36:35-41. 22. Tisdale JE, Sun H, Zhao H, Fan C, Colucci RD, Kluger J, Chow MSS. Antifibrillatory effect of esmolol alone and in combination with lidocaine. J Cardiovasc Pharmacol


7

Journal Articles (cont'd): 1996; 27:376-382. 23. Tisdale JE, Shimoyama H, Sabbah HN, Webb CR. The effect of cocaine on ventricular fibrillation threshold in the normal canine heart. Pharmacotherapy 1996;16:429-37. 24. Tisdale JE, Ducharme MP, Shimoyama H, Webb CR, Sabbah HN, Edwards DJ.

Electrophysiologic and electrocardiographic pharmacodynamics of cocaine. Pharmacotherapy 1996;16:438-445. 25. Tisdale JE, Padhi ID, Ware JA, Svensson CK. Comparison of fluorescence polarization immunoassay with liquid chromatography for quantification of procainamide and N- acetylprocainamide in urine. Ther Drug Monit 1996;18:693-697. 26. American Society of Health-System Pharmacists. ASHP therapeutic guidelines on angiotensin- converting-enzyme inhibitors in patients with left ventricular dysfunction.

Am J Health-Syst Pharm 1997;54:299-313. (Expert panel members who authored this paper were: Bottorff MB, Hilleman DE, Lopez LM, Munger MA, Nolan PE, Patterson JH, Tisdale JE).

27. Sharma ND, Rosman HS, Padhi ID, Tisdale JE. Torsades de pointes associated with

intravenous haloperidol in critically ill patients. Am J Cardiol 1998;81:238-240. 28. Tisdale JE, Padhi ID, Goldberg AD, Silverman NA, Webb CR, Higgins RS, Paone G,

Frank DM, Borzak S. A randomized, double-blind comparison of intravenous diltiazem and digoxin for atrial fibrillation following coronary artery bypass surgery. Am Heart J 1998;135:739-747.

29. Borzak S, Tisdale JE, Amin NB, Goldberg AD, Frank D, Padhi ID, Higgins RSD. Atrial

fibrillation after bypass surgery. Does the arrhythmia or the characteristics of the patients prolong hospital stay? Chest 1998;113:1489-1491.

30. Amin N, Borzak S, Housholder SA, Tisdale JE. Multiple episodes of sinus arrest

following the administration of ibutilide in a patient with underlying sinus node dysfunction. Heart 1998;79:628-9.

31. Tisdale JE. Antiplatelet therapy in coronary artery disease: Review and update of

efficacy studies. Am J Health-Syst Pharm 1998;55:S8-S16. 32. Zed P, Tisdale JE, Borzak S. Low molecular weight heparins in acute coronary


8

Journal Articles (cont'd): syndromes. Arch Intern Med 1999;159:1849-1857. 33. Tisdale JE. Drug-related problems: much ado about something. Can J Hosp Pharm

2000;53:314-316. 34. Moser LR, Tisdale JE, Smythe MA. Calcium pretreatment for prevention of hypotension

associated with intravenous calcium channel blockers. Ann Pharmacother 2000;34:622-629.

35. Slavik RS, Tisdale JE, Borzak S. Pharmacological conversion of atrial fibrillation: a

systematic review of available evidence. Prog Cardiovasc Dis 2001;44:121-152. 36. Tran AH, Yrigoyen LG, Racine E, Tisdale JE. Use of dofetilide in atrial fibrillation and atrial flutter. J Am Pharm Assoc 2001;41:747-759. 37. Tisdale JE, Rasty S, Padhi ID, Sharma N, Rosman H. The effect of intravenous haloperidol on QT interval dispersion in critically ill patients: comparison with QT

interval prolongation for assessment of risk of Torsades de Pointes. J Clin Pharmacol 2001;41:1310-1318. (Erratum in: J Clin Pharmacol 2002;42:577-9.)

38. Tisdale JE. Teaching and mentorship – invaluable contributions to the profession. Can J

Hosp Pharm 2002:55;192-194. 39. Rasty S, Borzak S, Tisdale JE. Bleeding associated with eptifibatide targeting higher-

risk patients: incidence and multivariate risk factors. J Clin Pharmacol 2002;42:1366-1373.

40. Tisdale JE. Indexing of journals in MEDLINE, PubMed and other bibliographic databases – why not CJHP? Can J Hosp Pharm 2004;57:77-78. 41. Amankwa K, Krishnan CK, Tisdale JE. Torsades de pointes associated with

fluoroquinolones. Importance of concomitant risk factors. Clin Pharmacol Ther 2004;75:242-7.

42. Rasty S, Amin NB, Sabbah HN, Mishima T, Borzak S, Tisdale JE. Influence of IV

haloperidol on ventricular repolarization and monophasic action potential duration in anesthetized dogs. Chest 2004;125:1821-1829.

43. Tisdale JE, Huang MB, Borzak S. Risk factors for hypertensive crisis: importance of


9

Journal Articles (cont’d): out-patient blood pressure control. Fam Pract 2004;21:420-424. 44. Tisdale JE. Role of the pharmacist in managing hypertension in patients with diabetes.

Am J Health-Sys Pharm 2006;63:1129. 45. Dager WE, Sanoski C, Wiggins B, Tisdale JE. Pharmacotherapy considerations in

advanced cardiac life support. Pharmacotherapy 2006;26:1703-1729. 46. Tisdale JE, Borzak S, Goldstein S, Shimoyama H, Sabbah HN. Hemodynamic and neurohormonal predictors and consequences of the development of atrial fibrillation in dogs with chronic heart failure. J Cardiac Fail 2006;12:747-51. 47. Tisdale JE. Pharmacist? What pharmacist? Can J Hosp Pharm 2006;59:235-236. 48. Tisdale JE, Kovacs R, Mi D, McCabe GP, Cariera BL, Sharma N, Rosman H. Accuracy of uncorrected versus corrected QT interval for prediction of torsades de pointes

associated with intravenous haloperidol. Pharmacotherapy 2007;27:175-82. 49. Buckley MS, Nolan PE Jr, Slack MK, Tisdale JE, Hilleman DE, Copeland JG.

Amiodarone prophylaxis for atrial fibrillation after cardiac surgery: meta-analysis of dose response and timing of initiation. Pharmacotherapy 2007;27:360-368.

50. Tisdale JE, Wroblewski HA, Hammoud ZT, Rieger KM, Young JV, Wall DS, Kesler

KA. Prospective evaluation of serum amiodarone concentrations when administered via a nasogastric tube into the stomach conduit after transthoracic esophagectomy. Clin Ther

2007;29:2226-34. 51. Dopp AL, Miller JM, Tisdale JE. Effect of drugs on defibrillation capacity. Drugs

2008;68:607-630. 52. Overholser BR, Zheng X, Tisdale JE. Catecholaminergic effects on ventricular

repolarization during inhibition of the rapid component of the delayed rectifier potassium current in a perfused heart model. Pharmacotherapy 2008;28:1315-1324.

53. Tisdale JE. Medication reconciliation – who, and how? Can J Hosp Pharm 2008;61:241-

242. 54. Tisdale JE, Overholser BR, Sowinski KM, Wroblewski HA, Amankwa K, Borzak S,

Coram R, Kingery J, Zipes DM, Flockhart DA, Kovacs RJ. Pharmacokinetics of ibutilide


10

Journal Articles (cont’d): in patients with heart failure due to left ventricular systolic dysfunction.

Pharmacotherapy 2008;28:1461-1470. 55. Weitzel KW, Tisdale JE, Mattingly J. APhA 2009 House of Delegates: serving the

Association and the profession. J Am Pharm Assoc 2009;49:474-480. 56. Tisdale JE, Wroblewski HA, Wall DS, Rieger KM, Hammoud ZT, Young JV, Kesler

KA. A randomized trial evaluating amiodarone for prevention of atrial fibrillation after pulmonary resection. Ann Thorac Surg 2009;88:886-895.

57. Overholser BR, Zheng X, Tisdale JE. Paroxysmal β-adrenergic receptor mediated

alterations in ventricular repolarization at rapid heart rates during inhibition of delayed rectifier currents. J Cardiovasc Pharmacol 2009;54:253-262.

58. Tisdale JE. Integrity in authorship and publication. Can J Hosp Pharm 2009;62:441-442. 59. Tisdale JE, Wroblewski HA, Wall DS, Rieger KM, Hammoud ZT, Young JV, Kesler

KA. A randomized, controlled study of amiodarone for prevention of atrial fibrillation after transthoracic esophagectomy. J Thorac Cardiovasc Surg 2010;140:45-51.

60. Tisdale JE, Wroblewski HA, Kesler KA. Prophylaxis of atrial fibrillation after

noncardiac thoracic surgery. Semin Thorac Cardiovasc Surg 2010;22:310-320. 61. Tisdale JE. Toward a unified model for contemporary institutional pharmacy practice.

Can J Hosp Pharm 2011;64:97-99. 62. Tisdale JE, Overholser BR, Wroblewski HA, Sowinski KM. The influence of

progesterone alone and in combination with estradiol on ventricular action potential duration and triangulation in response to potassium channel inhibition. J Cardiovasc Electrophysiol 2011;22:325-331.

63. Fernando HC, Jaklitsch MT, Walsh GL, Tisdale JE, Bridges CD, Mitchell JD, Shrager

JB. The Society of Thoracic Surgeons practice guideline on the prophylaxis and management of atrial fibrillation associated with general thoracic surgery: executive summary. Ann Thorac Surg 2011;92:1144-52.

64. Tisdale JE, Wroblewski HA, Overholser BR, Kingery JR, Trujillo TN, Kovacs RJ.

Prevalence of QT interval prolongation in patients admitted to cardiac care units and frequency of subsequent administration of QT interval-prolonging drugs. A prospective,


11

Journal Articles (cont’d): observational study in a large urban academic medical center in the US. Drug Saf

2012;35:459-470. 65. Wroblewski HA, Kovacs RJ, Kingery JR, Overholser BR, Tisdale JE. High risk of QT

interval prolongation and torsades de pointes associated with intravenous quinidine used for the treatment of resistant malaria or babesiosis. Antimicrob Agents Chemother 2012;56:4495-4499.

66. Hall KW, Musing E, Miller DA, Tisdale JE. Experiential training for pharmacy students:

time for a new approach. Can J Hosp Pharm 2012;65:285-293. 67. Kaakeh Y, Overholser BR, Lopshire J, Tisdale JE. Drug-induced atrial fibrillation.

Drugs 2012;72:1617-1630. 68. Tisdale JE, Hall KW. Hospital pharmacy in Canada. Ahead of the curve. Can J Hosp

Pharm 2012;65:345-346. 69. Tisdale JE, Overholser BR, Sowinski KM, Wroblewski HA, Amankwa K, Borzak S,

Coram R, Kingery J, Zipes DM, Flockhart DA, Kovacs RJ. Enhanced sensitivity to drug-induced QT interval lengthening in patients with heart failure due to left ventricular systolic dysfunction. J Clin Pharmacol 2012;52:1296-1305.

70. Mohamed AN, Abdelhady AM, Spencer D, Sowinski KM, Tisdale JE, Overholser BR.

Pharmacokinetic modeling and simulation of procainamide and N-acetylprocainamide in a patient receiving continuous renal replacement therapy: a novel approach to guide renal dose adjustments (research letter). Am J Kidney Dis 2013;61:1046-1048.

71. Tisdale JE, Jaynes HA, Kingery JR, Mourad NA, Trujillo TN, Overholser BR, Kovacs

RJ. Development and validation of a risk score to predict QT interval prolongation in hospitalized patients. Circ Cardiovasc Qual Outcomes 2013;6:479-487.

72. Trinkley KE, Page II RL, Lien H, Yamanouye K, Tisdale JE. QT interval prolongation

and the risk of torsades de pointes: essentials for clinicians. Curr Med Res Opin 2013;29:1729-1736.

73. Tisdale JE, Jaynes HA, Kingery JR, Overholser BR, Mourad NA, Trujillo TN, Kovacs

RJ. Effectiveness of a clinical decision support system for reducing the risk of QT interval prolongation in hospitalized patients. Circ Cardiovasc Qual Outcomes 2014;7:381-390.


12

Journal Articles (cont’d): 74. Tisdale JE. Can I get a guideline to help me interpret treatment guidelines? Can J Hosp

Pharm 2014;67:181-182. 75. Tisdale JE. What causes some patients with drug-induced QT interval prolongation to

develop torsades de pointes but not others? The elusive missing link. Drugs Aging 2014;31:577-579.

76. Frendl G, Sodickson AC, Chung MK, Waldo AL, Gersh BJ, Tisdale JE, Calkins H,

Aranki S, Kaneko T, Cassivi S, Smith SC Jr, Darbar D, Wee JO, Waddell TK, Amar D, Adler D. 2014 AATS guidelines for the prevention and management of perioperative atrial fibrillation and flutter for thoracic surgical procedures. Executive summary. J Thorac Cardiovasc Surg 2014;148:772-791.

77. Frendl G, Sodickson AC, Chung MK, Waldo AL, Gersh BJ, Tisdale JE, Calkins H,

Aranki S, Kaneko T, Cassivi S, Smith SC Jr, Darbar D, Wee JO, Waddell TK, Amar D, Adler D. 2014 AATS guidelines for the prevention and management of perioperative atrial fibrillation and flutter for thoracic surgical procedures. J Thorac Cardiovasc Surg 2014;148:e153-193.

78. Tisdale JE, Allen MR, Overholser BR, Jaynes HA, Kovacs RJ. Influence of zoledronic

acid on atrial electrophysiological parameters and electrocardiographic measurements. J Cardiovasc Electrophysiol 2015;26:671-677.

79. Tisdale JE. Drug-induced QT interval prolongation in children – are the kids alright?

Can J Hosp Pharm 2016;69:183-184. 80. Tisdale JE. Drug-induced QT interval prolongation and torsades de pointes – role of the

pharmacist in risk assessment, prevention and management. Can Pharm J 2016;149:139-152.

81. Abdelhady AM, Shugg T, Thong N, Lu JB, Kreutz Y, Jaynes HA, Robarge JD, Tisdale

JE, Desta Z, Overholser BR. Efavirenz inhibits the human ether-a-go-go related current (hERG) and induces QT interval prolongation in CYP2B6*6*6 allele carriers. J Cardiovasc Electrophysiol 2016;27:1206-1213.

82. Melton BL, Zillich AJ, Saleem J, Russ AL, Tisdale JE, Overholser BR. Iterative

development and evaluation of a pharmacogenomic-guided clinical decision support system for warfarin dosing. Appl Clin Inform 2016;7:1088-1106.


13

Journal Articles (cont’d): 83. Tisdale JE, Jaynes HA, Overholser BR, Sowinski KM, Flockhart DA, Kovacs RJ.

Influence of oral progesterone administration on drug-induced QT interval lengthening. A randomized, placebo-controlled crossover trial. JACC Clin Electrophysiol 2016;2:765-774.

84. Tisdale JE. Prevalence and significance of acquired QT interval prolongation in

hospitalized patients. Heart Rhythm 2017;14:979-980. 85. Tisdale JE. Editorial commentary: Optimization of dose selection for non-vitamin K

antagonist oral anticoagulants. Trends Cardiovasc Med 2017;27:573-574. 86. Alburikan KA, Aldemerdash A, Savitz ST, Tisdale JE, Whitsel EA, Soliman EZ,

Thudium EM, Sueta CA, Kucharska-Newton AM, Stearns SC, Rodgers JE. Contributions of medications and risk factors to QTc interval lengthening in the atherosclerosis risk in communities (ARIC) Study. J Eval Clin Pract 2017;23:1274-1280.

87. Tisdale JE. Research conducted by hospital pharmacists: an integral component of daily

practice or unrealistic expectation? Can J Hosp Pharm 2018;71:95-96. 88. Ko JS, Guo S, Hassel J, Celestino-Soper P, Lynnes TC, Tisdale JE, Zheng JJ, Taylor SE,

Foroud T, Murray MD, Kovacs RJ, Li X, Lin SF, Chen Z, Vatta M, Chen PS, Rubart M. Ondansetron blocks wildtype and p.F503L variant small conductance calcium activated potassium channels. Am J Physiol Heart Circ Physiol 2018; Apr 20. doi: 10.1152/ajpheart.00479.2017. [Epub ahead of print]

89. Tomaselli Muensterman E, Tisdale JE. Predictive analytics for identification of patients

at risk for QT interval prolongation – a systematic review. Pharmacotherapy 2018 (In press).

90. Tisdale JE, Jaynes HA, Watson MR, Corya AL, Shen C, Kesler KA. Amiodarone for

prevention of atrial fibrillation following esophagectomy: a propensity score-matched analysis. (Submitted).

91. Tisdale JE, Jaynes HA, Overholser BR, Sowinski KM, Flockhart DA, Kovacs RJ.

Influence of progesterone administration on drug-induced torsades de pointes in AV-node ablated isolated perfused rabbit hearts. (Manuscript in preparation).

92. Tisdale JE, Jaynes HA, Overholser BR, Sowinski KM, Fisch MD, Rodgers JE,

Aldemerdash A, Hsu C-C, Wang N, Muensterman ET, Rao V, Kovacs RJ. Enhanced


14

Journal Articles (cont’d): response to drug-induced QT interval lengthening in patients with heart failure with preserved ejection fraction. (Manuscript in preparation).

93. Zarowitz BJ, Tisdale JE. Navigating the mine field of QTc-prolonging therapy in older

adults. (Manuscript in preparation). 94. Tisdale JE, Tomaselli Muensterman E, Overholser BR, Jaynes HA, Kovacs RJ. New-

onset atrial fibrillation associated with bisphosphonate drugs: a systematic review of randomized and nonrandomized trials. (Manuscript in preparation)

94. Muensterman ET, Jaynes HA, Overholser BR, Sowinski KM, Kovacs RJ, Tisdale JE.

Testosterone attenuates drug-induced QT interval lengthening in older men. (Manuscript in preparation).

95. Tisdale JE, Jaynes HA, Corya AL, Watson W, Kesler KA. Dose-related pulmonary

toxicity and other adverse effects associated with intravenous amiodarone when used for prophylaxis and treatment of atrial fibrillation following pulmonary resection: a propensity score-matched analysis. (Manuscript in preparation).

Books: 1. Tisdale JE, Miller DA (eds). Drug-Induced Diseases: Prevention, Detection and

Management. Bethesda; American Society of Health-System Pharmacists: 2005. 2. Tisdale JE, Miller DA (eds). Drug-Induced Diseases: Prevention, Detection and

Management, 2nd ed. Bethesda; American Society of Health-System Pharmacists: 2010. 3. Baker WL, Beavers C, Bolesta S, Chow S, Coons J, Cooper-DeHoff R, Dixon DL,

Dobesh P, Ensor C, Finks S, Jennings D, McConnell K, Oliphant C, Page II R, Parker M, Rogers K, Spencer D, Tisdale JE, eds. Updates in TherapeuticsÒ: Cardiology Pharmacy Preparatory Review Course, 2018 ed. Lenexa, KS: American College of Clinical Pharmacy: 2018.

3. Tisdale JE, Miller DA (eds). Drug-Induced Diseases: Prevention, Detection and

Management, 3nd ed. Bethesda; American Society of Health-System Pharmacists: (In press, anticipated publication September 2018).


15

Book Chapters: 1. Tisdale JE. Drug therapy for cardiac arrhythmias. In: McCormack JP, Brown G, Levine

M, Rangno R, Ruedy J (eds). Drug therapy decision making guide. Philadelphia: W.B. Saunders, Inc., 1996:22-30.

2. Parker RB, Tisdale JE. Tachycardias. In: American College of Clinical Pharmacy. Pharmacotherapy Self-Assessment Program (PSAP), 3rd ed, Module 1: Cardiovascular;

1998:105-145. 3. Tisdale JE, Moser LM. Tachyarrhythmias. In: American College of Clinical Pharmacy. Pharmacotherapy Self-Assessment Program (PSAP), 4th ed, Book 1: Cardiovascular; 2001: 217-267. 4. Tisdale JE. Arrhythmias. In: Tisdale JE, Miller DA (eds). Drug-Induced Diseases:

Prevention, Detection and Management. Bethesda; American Society of Health-System Pharmacists: 2005:289-327. 5. Tisdale JE. Arrhythmias. In: Chisholm M, Schwinghammer T, Wells B, DiPiro J,

Kolesar J, Malone P (eds). Pharmacotherapy Principles & Practice. New York; McGraw-Hill: 2007;107-132.

6. Koehler JM, Tisdale JE. Hypertension. In: Schwinghammer TL, Koehler JM, eds.

Pharmacotherapy Casebook. A Patient-Focused Approach. 7th ed. New York; McGraw- Hill: 2008:39-42.

7. Miller DA, Tisdale JE. Evaluating patients for drug-induced diseases. In: Tisdale JE,

Miller DA (eds). Drug-Induced Diseases: Prevention, Detection and Management, 2nd ed. Bethesda; American Society of Health-System Pharmacists: 2010:40-47.

8. Tisdale JE. Supraventricular arrhythmias. In: Tisdale JE, Miller DA (eds). Drug-

Induced Diseases: Prevention, Detection and Management, 2nd ed. Bethesda; American Society of Health-System Pharmacists: 2010:445-484.

9. Tisdale JE. Ventricular arrhythmias. In: Tisdale JE, Miller DA (eds). Drug-Induced

Diseases: Prevention, Detection and Management, 2nd ed. Bethesda; American Society of Health-System Pharmacists: 2010:485-515.

10. Cook K, Tisdale JE. Cardiovascular. In: Hutchison LC, Sleeper-Irons RB (eds).

Fundamentals of Geriatric Pharmacotherapy. An Evidence-Based Approach. Bethesda; American Society of Health-System Pharmacists: 2010:121-161.


16

Book Chapters (cont’d): 11. Tisdale JE. Arrhythmias. In: Chisholm-Burns MA, Schwinghammer TL, Wells BG,

Malone PM, Kolesar JM, DiPiro JT, (eds). Pharmacotherapy Principles & Practice, 2nd ed. New York; McGraw-Hill: 2010:157-183.


Pharmacotherapy Casebook. A Patient-Focused Approach. 8th ed. New York; McGraw- Hill: 2011;57-60.

13. Tisdale JE. Review of cardiac arrhythmias and rhythm interpretation. In: Wiggins BS,

Sanoski CA, eds. Emergency Cardiovascular Pharmacotherapy. A Point-of-Care Guide. Bethesda; American Society of Health-System Pharmacists: 2012:13-48.

14. Tisdale JE. Arrhythmias. In: Chisholm-Burns MA, Wells BG, Schwinghammer TL,

Malone PM, Kolesar JM, DiPiro JT (eds). Pharmacotherapy Principles & Practice, 3rd ed. New York; McGraw-Hill: 2013:169-195.


Pharmacotherapy Casebook. A Patient-Focused Approach. 9th ed. New York; McGraw- Hill: 2014:57-60.


Wells BG, Malone PM, Kolesar JM, DiPiro JT (eds). Pharmacotherapy Principles & Practice, 4th ed. New York; McGraw-Hill: 2016;137-161.

17. Tisdale JE. Acute management of arrhythmias. In: Erstad B, ed. Critical Care

Pharmacotherapy. Lenexa, KS; American College of Clinical Pharmacy: 2016;1244-1281.

18. Koehler JM, Tisdale JE. Hypertension. In: Schwinghammer TL, Koehler JM, Borchert

JS, Slain D, Park SK, eds. Pharmacotherapy Casebook. A Patient-Focused Approach. 10th ed. New York; McGraw-Hill: 2017;53-56.

19. Tisdale JE. Arrhythmias. In: Baker WL, Beavers C, Bolesta S, Chow S, Coons J,

Cooper-DeHoff R, Dixon DL, Dobesh P, Ensor C, Finks S, Jennings D, McConnell K, Oliphant C, Page II R, Parker M, Rogers K, Spencer D, Tisdale JE, eds. Updates in TherapeuticsÒ: Cardiology Pharmacy Preparatory Review Course, 2018 ed. Lenexa, KS: American College of Clinical Pharmacy: 2018; 445-524.

20. Miller DA, Tisdale JE. Evaluating patients for drug-induced diseases. In: Tisdale JE,


17

Book Chapters (cont’d):

Miller DA (eds). Drug-Induced Diseases: Prevention, Detection and Management, 3rd ed. Bethesda; American Society of Health-System Pharmacists: 2018 (In press).

21. Tisdale JE. Ventricular arrhythmias. In: Tisdale JE, Miller DA (eds). Drug-Induced

Diseases: Prevention, Detection and Management, 3rd ed. Bethesda; American Society of Health-System Pharmacists: 2018 (In press).

22. Tisdale JE. Supraventricular arrhythmias. In: Tisdale JE, Miller DA (eds). Drug-

Induced Diseases: Prevention, Detection and Management, 3rd ed. Bethesda; American Society of Health-System Pharmacists: 2018 (In press).


Wells BG, Malone PM, Kolesar JM, DiPiro JT (eds). Pharmacotherapy Principles & Practice, 5th ed. New York; McGraw-Hill: 2019 (In press).

Other Publications: 1. Tisdale JE, Zarowitz BJ, Miller DA, Slaughter RL. Comment: The Pharm.D.: all or some?

(letter). DICP Ann Pharmacother 1991;25:680-1. 2. Tisdale JE. Software review: Cardiac Emergency Simulator. Am J Hosp Pharm 1992;49:236-7. 3. Tisdale JE. Book review: Guide to Clinical Trials. Clin Pharm 1992;11:277. 4. Tisdale JE, Hart SM. Book review: Life in the Balance: Emergency Medicine and the Quest to Reverse Sudden Death. Am J Health-Syst Pharm 1998;55:1534-5.

5. Tisdale JE. Foreword. In: Murphy JE, ed. Resident Survival Guide. Lenexa, KS;

American College of Clinical Pharmacy: 2011;vii-viii.

6. Tisdale JE. Commentary on: Tsuyuki RT et al. The effectiveness of pharmacist interventions on cardiovascular risk: The Multicenter Randomized Controlled RxEACH Trial. Practice Update website, 2016. J Am Coll Cardiol 2016;67:2846-2854. Available at: http://www.practiceupdate.com/content/the-effectiveness-of-pharmacist-interventions-on-cardiovascular-risk/40704/65/2/1.

7. Tisdale JE. Commentary on: Wiggins BS, et al. Recommendations for management of

clinically significant drug-drug interactions with statins and select agents used in patients


18

Other Publications (cont’d): with cardiovascular disease: a scientific statement from the American Heart Association. Practice Update website, 2016. Circulation 2016;134:e468-e495. Available at: http://www.practiceupdate.com/journalscan/31928/1/2?elsca1=emc_enews_expert-insight&elsca2=email&elsca3=practiceupdate_cardio&elsca4=cardiology&elsca5=newsletter&rid=MjA4MTU0NjY4NTM1S0&lid=10332481

8. Tisdale JE. Commentary on: Andrews J et al. Warfarin use is associated with

progressive coronary arterial calcification: insights from serial intravascular ultrasound. JACC Cardiovasc Imag 2017. Practice Update website, 2017. Available at: http://www.practiceupdate.com/content/warfarin-use-is-associated-with-progressive-coronary-arterial-calcification/56095/65/2/1

Abstracts: 1. Tisdale J. An evaluative study of the current drug distribution system in two pediatric

critical care units. Proceedings of the 19th Annual American Society of Hospital Pharmacists Midyear Clinical Meeting, Dallas, Texas, December 5, 1984. 2. Tisdale JE, Kluger J, Fisher JR, Chow MSS. Efficacy of class 1C antiarrhythmic agents in patients with inducible ventricular tachycardia refractory to class 1A drugs. J Clin

Pharmacol 1989;29:855. 3. Tisdale JE, Fisher JR, Chow MSS, Kluger J. Efficacy of subsequent therapy with an alternate class 1C antiarrhythmic agent in patients with inducible ventricular tachycardia

on initial class 1C antiarrhythmic therapy. J Clin Pharmacol 1989;29:855. 4. Tisdale JE, Chow MSS, Fisher JR, Kluger J. Nature of mexiletine-induced adverse effects in patients with ventricular arrhythmias. Proceedings of the 24th Annual American Society of Hospital Pharmacists Midyear Clinical Meeting, December 5, 1989,

Atlanta, Georgia. 5. Tisdale JE, Zhao H, Sun H, Fan C, Colucci RD, Kluger J, Fieldman A, Chow MSS. The antifibrillatory effects of esmolol and lidocaine alone and in combination. Clin Pharmacol Ther 1990;47:140. 6. Sun H, Tisdale JE, Fan C, Colucci RD, Zhao H, Kluger J, Fieldman A, Chow MSS. Cardiovascular pharmacodynamics of esmolol. Clin Pharmacol Ther 1990;47:196. 7. Tisdale JE, Colucci RD, Ujhelyi M, Kluger J, Fieldman A, Chow MSS. Evaluation of


19

Abstracts (cont'd): adverse effects of tissue plasminogen activator (t-PA) and streptokinase. Pharmacotherapy 1990;10:247-8. 8. Tisdale JE, Kambe JC, Chow MSS, Yeston NS. The effect of haloperidol on ventricular fibrillation threshold in pigs. J Clin Pharmacol 1990;30:860. 9. Fan C, Tisdale JE, Ujhelyi MR, Chow MSS. Effect of filter binding on unbound plasma quinidine concentrations determined by ultrafiltration. Proceedings of the 25th Annual American Society of Hospital Pharmacists Midyear Clinical Meeting, December

2-6, 1990, Las Vegas, Nevada. 10. Chow MS, Ujhelyi MR, Podurgiel S, Gentile NT, Tisdale JE, Fan C, Kluger J, Fieldman

A. Hemodynamic consequences of nimodipine administration during cardiopulmonary resuscitation (CPR). Clin Pharmacol Ther 1991;49:189.

11. Tisdale JE, Outman WR, Bleske BE, Chow MSS, Izard M, Mortillo M, Jensen BK. The pharmacokinetics of rimantadine in patients with mild or moderate renal dysfunction and in healthy subjects. Pharmacotherapy 1992;12:249. 12. Frame DG, Tisdale JE, Borzak S, Slaughter RL. Are there gender and race differences in the use of thrombolytic agents? Pharmacotherapy 1993;13:270. 13. Tisdale JE, Follin SL, Webb CR. Risk factors for amiodarone toxicity. J Clin Pharmacol

1993;33:1006. 14. Tisdale JE, Shimoyama H, Webb CR. Effect of cocaine on ventricular fibrillation threshold. J Clin Pharmacol 1993;33:1006. 15. Tisdale JE, Ducharme MP, Shimoyama H, Webb CR, Edwards DJ. Cardiovascular pharmacodynamics of cocaine. Clin Pharmacol Ther 1994;55:203. 16. Tisdale JE, Rudis MI, Padhi ID, Borzak S, Svensson CK, Webb CR, Ware JA, Krepostman A, Zarowitz BJ. Procainamide pharmacokinetics in congestive heart failure. Clin Pharmacol Ther 1995;57:142. 17. Tisdale JE, Rudis MI, Padhi ID, Svensson CK, Webb CR, Borzak S, Ware JA, Krepostman A, Zarowitz BJ. Inhibition of procainamide N-acetylation by para- aminobenzoic acid (PABA). Clin Pharmacol Ther 1995;57:184.


20

Abstracts (cont'd): 18. Tisdale JE, Padhi ID, Ware JA, Svensson CK. Fluorescence polarization immunoassay (F) for quantification of procainamide (PA) and N-acetylprocainamide (NAPA) in urine.

Clin Pharmacol Ther 1996;59:213. 19. Sharma N, Rosman H, Padhi ID, Tisdale JE. QTc interval prolongation and torsades de

pointes associated with intravenous haloperidol - a case control study. J Investig Med 1996;44:210A. 20. Tisdale JE, Padhi ID, Goldberg AD, Silverman NA, Webb CR, Higgins RS, Paone G, Frank DM, Borzak S. Diltiazem controls ventricular rate more rapidly but not more

effectively than digoxin in patients with atrial fibrillation following coronary artery bypass surgery. Circulation 1996;94(Suppl. I):I-90.

21. Tisdale JE, Padhi ID, Sharma ND, Rosman H. Intravenous haloperidol prolongs QT

interval and increases QT interval dispersion in critically ill patients. Circulation 1996;94(Suppl. I):I-245. 22. Sharma ND, Rosman HS, Padhi ID, Tisdale JE. Torsades de pointes associated with intravenous haloperidol in critically ill patients: incidence and influence on length of hospital stay. J Am Coll Cardiol 1997;29:34A. 23. Borzak S, Tisdale JE, Amin NB, Goldberg AD, Webb CR, Padhi ID, Frank DM, Jacobsen G, Paone G, Higgins RSD, Silverman NA. Atrial fibrillation after bypass surgery: Does the arrhythmia or the characteristics of the patients prolong hospital stay? Circulation 1997;96:I-616-7. 24. Tisdale JE, Huang MB, Borzak S. Pharmacological and nonpharmacological risk factors

for hypertensive crisis. Clin Pharmacol Ther 1999;65:130. 25. Amin NB, Tisdale, JE, Sharma N, Rosman H. Risk factors for QTc interval prolongation

induced by intravenous haloperidol. Clin Pharmacol Ther 1999;65:147. 26. Nolan PE, Tisdale JE, Spinler SA, Hilleman DE, Slack MK. Meta-analysis of the antiarrhythmic effects of prophylactic amiodarone following cardiac surgery. Pharmacotherapy 1999;19:1197. 27. Rasty S, Borzak S, Held AC, Kraft P, Tisdale JE. Safety of targeted institutional

guidelines for eptifibatide in high-risk patients with acute coronary syndromes - is bleeding increased? Clin Pharmacol Ther 2000; 67:119.


21

Abstracts (cont'd): 28. Nolan PE, Tisdale JE, Spinler SA, Hilleman DE, Slack MK. Meta-analysis of the

antiarrhythmic effects of prophylactic sotalol following cardiac surgery. Pharmacotherapy 2000;20:339.

29. Tisdale JE, Rasty S, Amin NB, Borzak S, Mishima T, Sabbah HN. Influence of haloperidol on electrophysiological mechanisms of torsades de pointes in dogs. Eur

Heart J 2000;21:440. 30. Tisdale JE, Smythe MA, Anandan JV, Munzenberger PJ. A process-oriented course for teaching a systematic approach to prevention, identification and resolution of

drug-related problems (DRPs). Am J Pharm Educ 2001;65:105S-106S. 31. Overholser BR, Tisdale JE, Cariera BL, Sowinski KM. Mechanism-based modeling of the effects of ibutilide on ventricular repolarization in patients with atrial fibrillation. Clin Pharmacol Ther 2004;75:P97. 32. Buckley MS, Nolan PE, Slack MK, Tisdale JE, Hilleman DE. Prophylactic amiodarone decreases atrial fibrillation and hospital length of stay following cardiac surgery: a meta- analysis. Pharmacotherapy 2004;24:1426. 33. Buckley MS, Nolan PE, Slack MK, Tisdale JE, Hilleman DE. Amiodarone dose- response for preventing atrial fibrillation following cardiac surgery: a meta-analysis. Pharmacotherapy 2004;24:1426. 34. Cariera BL, Kovacs R, Mi D, McCabe GP, Lisek C, Tisdale JE. Accuracy of uncorrected vs corrected QT interval for prediction of drug-induced torsades de pointes. Circulation 2004;110:III-580. 35. Tisdale JE, Wroblewski H, Rieger K, Hammoud Z, Young JV, Brooks JA, Wall D,

Kesler KA. Poor absorption of amiodarone administered via nasogastric tube into the stomach conduit in patients following thoracoabdominal esophagectomy.

Pharmacotherapy 2006;26:734. 36. Overholser BR, Zheng X, Tisdale JE. Contrasting early versus delayed effects of

catecholamines on cardiac repolarization. Pharmacotherapy 2007;27:192. 37. Nystrom P, Desta Z, Jakubowski J, Li L, Hilligoss J, Tisdale JE, Kreutz Y, Miao J,

Flockhart DA, Kovacs R, Jin Y. Response to clopidogrel in patients with coronary artery


22

Abstracts (cont'd): disease is associated with CYP2C19 but not CYP2B6 genotype. Clin Pharmacol Ther 2008;83:S3-S4.

38. Tisdale JE, Overholser BR, Wroblewski HA, Sowinski KM. Influence of female sex

hormones on ventricular action potential response to potassium channel inhibition. Clin Pharmacol Ther 2009:85:S6.

39. Overholser BR, Zheng X, Li L, Tisdale JE. Beta-adrenergic mediated alterations of IKs

activity during IKr inhibition. Clin Pharmacol Ther 2009;85:S6-S7. 40. Tisdale JE, Overholser BR, Sowinski KM, Wroblewski HA, Amankwa K, Borzak S,

Kingery JR, Coram R, Zipes DM, Flockhart DA, Kovacs RJ. Increased myocardial sensitivity to IKr inhibition in patients with heart failure due to left ventricular systolic dysfunction. Circulation 2009;120:S640.

41. Wroblewski HA, Tisdale JE, Kingery JR, Overholser BR, Kovacs RJ. Prevalence of

QTc interval prolongation in patients admitted to cardiac critical care units & frequency of subsequent administration of QT interval prolonging drugs. J Am Coll Cardiol 2010;55:A1.E10.

42. Wroblewski HA, Tisdale JE, Kingery JR, Overholser BR, Kovacs RJ. Adverse drug

events resulting in admissions to a cardiac care unit. J Am Coll Cardiol 2010;55:A50.E476.

43. Tisdale JE, Wroblewski HA, Kingery JA, Trujillo TN, Overholser BR, Kovacs RJ. A

risk score to predict QT interval prolongation in hospitalized patients. J Am Coll Cardiol 2011;57:E112.

44. Melton BL, Zillich AJ, Saleem JJ, Russ AL, Tisdale JE, Overholser BR. Usability

testing to refine a pharmacogenomic-guided warfarin clinical decision support system. Proceedings of the 35th Symposium of the American Medical Informatics Association (AMIA); 2011:1888.

45. Tisdale JE, Wroblewski HA, Kim G, Overholser BR, Kingery JR, Kovacs RJ. Acute

kidney injury associated with intravenous furosemide: incidence, independent risk factors, and clinical consequences. J Am Coll Cardiol 2012;59:A253.

46. Tisdale JE, Wroblewski HA, Kingery JR, Overholser BR, Trujillo TN, Kovacs RJ.

Effectiveness of a clinical decision support system incorporating a validated QT interval


23

Abstracts (cont'd): prolongation risk score for reducing the risk of QT interval prolongation in hospitalized patients. J Am Coll Cardiol 2012;59:A441.

47. Overholser BR, Lai X, Witzmann F, Tisdale JE, Rubart-Von der Lohe M, Hudmon A.

The KCNQ1 carboxy terminus is differentially phosphorylated in response to short- versus long-term β-adrenergic stimulation. Circulation 2012;126:A17494.

48. Abdelhady AM, Thong N, Kreutz Y, Tisdale JE, Desta Z, Overholser BR. Association

of the CYP2B6*6 allele with efavirenz-induced QT interval changes at steady state in healthy subjects. Clin Pharmacol Ther 2013;93:S22-23.

49. Tisdale JE, Allen MR, Overholser BR, Wroblewski HA, Kovacs RJ. Influence of

zoledronic acid on atrial electrophysiological parameters associated with risk of atrial fibrillation. J Am Coll Cardiol 2013;61:E270.

50. Shao M, Wei R, Tisdale JE, Liu W, Overholser BR. miR-362-3p decreases hERG expression and is associated with an unidentified form of congenital Long-QT syndrome. Circulation 2013;128:A18234.

51. Abdelhady AM, Shugg TA, Shao M, Tisdale JE, Desta Z, Overholser BR. Efavirenz

inhibits hERG-regulated potassium current in a concentration-dependent manner. Clin Pharmacol Ther 2014;95 (Supplement 1):S12-S13.

52. Alburikan KA, Savitz ST, Whitsel EA, Tisdale JE, Soliman E, Thudium EM, Sueta CA,

Kucharska-Newton AM, Stearns SC, Rodgers JE. Contribution of medications and risk factors to QT interval lengthening in the Atherosclerosis Risk in Communities (ARIC) Study. Circulation 2014;130:A13786.

53. Tisdale JE, Jaynes HA, Overholser BR, Sowinski KM, Flockhart DA, Kovacs RJ.

Influence of oral progesterone administration on QT interval response to IKr inhibition. Circulation 2014;130:A18740.

54. Jaynes HA, Tisdale J, Zillich A. Independent factors associated with emergency

department utilization in non-elderly patients with heart failure. J Am Coll Cardiol 2015;65:A1058.

55. Alburikan KA, Savitz ST, Whitsel EA, Tisdale JE, Soliman EZ, Kucharska-Newton

AM, Stearns SC, Rodgers JE. Predictors of the utilization of QT interval lengthening medications in the Atherosclerosis Risk in Communities (ARIC) study. Circ Cardiovasc


24

Abstracts (cont'd):

Qual Outcomes 2015;8:A141. 56. Mourad NA, Assiri A, Shao M, Tisdale J, Liu W, Overholser B. MicroRNA 362-3p

expression is upregulated in patients with heart failure. Heart Rhythm 2015;12:S97-98. 57. Ko J, Hassel J, Celestino-Soper P, Lynnes TC, Tisdale JE, Zheng JJ, Taylor S, Foroud T,

Murray MD, Kovacs R, Vatta M, Chen Z, Chen P-S, Rubart-von der Lohe M. The role of small conductance Ca activated K current in the genesis of drug-induced long QT syndrome. Heart Rhythm 2015;12:S489.

58. Alburikan KA, Savitz ST, Tisdale JE, Soliman EZ, Sueta CA, Stearns SC, Rodgers JE.

Cardiovascular QTc interval-prolonging medications and the risk of death, stroke and incident atrial fibrillation in the atherosclerosis risk in communities (ARIC) study. Circulation 2015;132:A19035.

59. Tisdale J, Jaynes H, Overholser B, Sowinski KM, Flockhart DA, Kovacs R. Influence of

progesterone administration on drug-induced torsades de pointes in AV node-ablated isolated perfused rabbit hearts. J Am Coll Cardiol 2016;67(13_S):747.

60. Egly C, Shugg T, Stamatkin CW, Patil AS, Tisdale JE, Overholser BR. Progesterone

metabolites alter activation gating of the human ether-a-go-go-related gene (hERG)- related current. Circulation 2016;134:A20786.

61. Tisdale JE, Jaynes HA, Watson M, Corya A, Kesler KA. Intravenous amiodarone for

prevention of atrial fibrillation following esophagectomy: a propensity score-matched analysis. J Am Coll Cardiol 2017;69(Supplement 21):545.

62. Faber A, Murray B, Abbaspour H, Jaynes H, Snyder M, Tisdale J, Kovacs R. Screening

for atrial fibrillation in community pharmacies. J Am Pharm Assoc 2017;57:e101. 63. Muensterman ET, Nader A, Abdullah A, Quinney S, Overholser BR, Jaynes HA, Tisdale

JE, Sowinski KM. Pharmacokinetic-pharmacodynamic (PKPD) modeling to identify predictors of response to the effect of progesterone on attenuation of drug-induced QT interval lengthening. J Pharmacokinet Pharmacodyn 2018 (In press).


25

Grant Support Title: Reducing the Risk of Drug-Induced QT Interval Lengthening in Women

(18TPA34170523) Award: Transformational Project Award Sponsor: American Heart Association Amount: $300,000 Date: July 1, 2018 – June 30, 2021 Role: Principal investigator Salary support: 10% Title: Screening for Atrial Fibrillation in Community Pharmacies Award: Atrial Fibrillation Awareness Sponsor: Heart Rhythm Society Amount: $5,000 Date: September 1, 2016 – December 31, 2016 Role: Principal investigator Title: Methadone-induced QT interval prolongation in a narcotic treatment center:

identifying patients at risk and simplifying ECG monitoring Award: Futures Grants Program Sponsor: American College of Clinical Pharmacy Research Institute Amount: $5,000 Date: July 1, 2016 – June 30, 2017 Role: Co-investigator and research mentor (PI: Erika Titus-Lay, PharmD) Title: MicroRNA Dysregulation of Cardiac Repolarization During Heart Failure

(16GRNT31080006) Award: Grant-in-Aid Sponsor: American Heart Association Midwest Affiliate Amount: $154,000 Date: July 1, 2016 – June 30, 2018 Role: Co-investigator (PI: Brian R. Overholser, PharmD) Title: Influence of Testosterone Administration on Drug-Induced QT Interval

Prolongation and Torsades de Pointes (15GRNT24470168) Award: Grant-in-Aid Sponsor: American Heart Association Midwest Affiliate Amount: $143,000 Date: July 1, 2015 – June 30, 2017 Role: Principal investigator


26

Grant Support (cont'd): Salary support: 5% year 1; 8% year 2 Title: Sensitivity to drug-induced QT interval lengthening in patients with heart failure

with preserved left ventricular ejection fraction Award: Center of Excellence in Cardiovascular Research (CECARE) Sponsor: Indiana Clinical Translational Sciences Institute (CTSI) Amount: $160,000 Date: November 1, 2012 – April 30, 2017 Role: Principal investigator Salary support: 5% Title: Influence of progesterone administration on drug-induced QT interval

prolongation and torsades de pointes (12GRNT12060187) Award: Grant-in-Aid Sponsor: American Heart Association Midwest Affiliate Amount: $143,000 Date: July 1, 2012 – June 30, 2014 Role: Principal investigator Salary support: 10% Title: Health & Hospital Corporation of Marion County Sponsor: Health & Hospital Corporation of Marion County Amount: $43,519 Date: July 1, 2012 – June 30, 2013 Role: Principal investigator Salary support: 20% Title: The effects of bisphosphonates on atrial electrophysiology Award: Pre-clinical project award Sponsor: Indiana University-Purdue University Clinical Translational Sciences Institute

(CTSI) Amount: $14,666 Date: September 1, 2010 – August 31, 2011 Role: Principal Investigator Title: Identification of the most common adverse drug reactions in hospitalized patients

and determination of independent risk factors Award: Lilly Seed Grant in Medication Safety Sponsor: Purdue University (from funds received in an endowment from the Lilly


27

Grant Support (cont'd): Foundation) Amount: $100,000 Date: July 1, 2010 – June 30, 2012 Role: Principal Investigator Funding rate: 1 of 5 submissions funded Salary support: 5% Title: Computer automated safety alerts for reduction of the risk of drug-induced torsades de pointes Award: Lilly Seed Grant in Medication Safety Sponsor: Purdue University (from funds received in an endowment from the Lilly Foundation) Amount: $100,000 Date: July 1, 2008 – June 30, 2010 Role: Principal Investigator Funding rate: 3 of 7 submissions funded Salary support: 5% Title: Integrating pharmacogenomic-guided dosing into clinical practice Award: Lilly Seed Grant in Medication Safety Sponsor: Purdue University (from funds received in an endowment from the Lilly

Foundation) Amount: $100,000 Date: July 1, 2008 – June 30, 2010 Role: Co-investigator Funding rate: 3 of 7 submissions funded Title: Sympathetic modulation of outward rectifier currents during atrial fibrillation Sponsor: American College of Clinical Pharmacy Frontiers Career Development Research Award Amount: $30,000 Date: July 1, 2007 – June 30, 2008 Role: Co-investigator Title: Female sex hormone effects on ventricular action potential duration & dispersion Sponsor: American College of Clinical Pharmacy Research Institute Award: Frontiers Career Development Research Award Amount: $29,663


28

Grant Support (cont'd): Date: July 1, 2006 – June 30, 2007 Role: Principal Investigator Title: Sympathetic activation of I(Ks) during I(Kr) inhibition Sponsor: American College of Clinical Pharmacy Research Institute and AstraZeneca Cardiovascular Research Award Amount: $17,500 Date: July 1, 2005 – June 30, 2006 Role: Co-investigator Title: Prevention of atrial fibrillation following non-cardiac thoracic surgery Sponsor: Gustavus & Louise Pfeiffer Research Foundation Amount: $74,327 Date: July 1, 2004 – June 30, 2005 Role: Principal Investigator Salary support: 25% Title: United States Pharmacopeia Fellowship Sponsor: United States Pharmacopeia Amount: $20,000 Date: July, 2004 – June, 2005 Role: Principal Investigator/Preceptor (Beth L. Cariera, Fellow) Comment: This award had to be returned to the sponsor because the fellow left the program prematurely during the year of this funding Title: Mechanisms of increased risk of torsades de pointes associated with potassium channel blocking agents in heart failure Award: Grant-in-Aid Sponsor: American Heart Association Greater Midwest Affiliate Amount: $131,887 Date: January 1, 2004 – December 31, 2005 Role: Principal Investigator Salary support: 23% Title: United States Pharmacopeia Fellowship Sponsor: United States Pharmacopeia Amount: $20,000 Date: July, 2003 – June, 2004 Role: Principal Investigator/Preceptor (Beth L. Cariera, Fellow)


29

Grant Support (cont'd): Title: Cardiovascular research support Sponsor: The Max Baer Heart Fund, Fraternal Order of Eagles of Illinois and Indiana Amount: $5,000 Date: 2003-2004 Role: Principal Investigator Title: Fellowship in cardiovascular pharmacotherapy Sponsor: Aventis Pharmaceuticals Amount: $15,000 Date: 2003-2004 Role: Principal Investigator/Preceptor Title: Fellowship in cardiovascular pharmacotherapy Sponsor: Aventis Pharmaceuticals Amount: $10,000 Date: 2002-2003 Role: Principal Investigator/Preceptor Title: Cardiology minisabbatical Sponsor: American College of Clinical Pharmacy Research Institute and Cardiology Practice & Research Network Amount: $2,700 Date: 2002-2003 Role: Principal Investigator Title: Degree of platelet inhibition achieved by recommended doses of eptifibatide in patients with non-ST segment elevation acute coronary syndromes and moderate or severe renal dysfunction Sponsor: Millennium Pharmaceuticals, Inc. Amount: $49,235 Date: 2002-2003 Role: Principal Investigator Comment: I could not accept the funding because of my move to Purdue University. Title: Fellowship in cardiovascular pharmacotherapy Sponsor: Aventis Pharmaceuticals, Inc. Amount: $61,822 Date: July, 2002 – June, 2004 Role: Principal Investigator/Preceptor


30

Grant Support (cont'd): Comment: I could not accept the funding because of my move to Purdue University. Title: Fellowship in cardiovascular pharmacotherapy Sponsor: Aventis Pharmaceuticals, Inc. Amount: $53,516 Date: July, 2000 – June, 2002 Role: Principal Investigator/Preceptor Title: Safety of institutional guidelines for eptifibatide use in high-risk patients with acute coronary syndromes Sponsor: Cor Therapeutics Amount: $18,202 Date: 1999-2000 Role: Principal Investigator Salary support: 10% Title: Influence of heart failure on the pharmacokinetics of ibutilide Award: Cardiovascular Research Award Sponsor: American College of Clinical Pharmacy Research Institute and Rhone-Poulenc Rorer Amount: $9,898 Date: 1999-2000 Role: Principal Investigator Title: Fellowship in cardiovascular pharmacotherapy Sponsor: Hoechst Marion Roussel Amount: $51,812 Date: July, 1998 – June, 2000 Role: Principal Investigator/Preceptor Title: Mechanisms of haloperidol-induced torsades de pointes Award: Small Projects Grant Sponsor: Henry Ford Hospital Amount: $9,898 Date: 1998-1999 Role: Principal Investigator Funding rate: 6 of 18 submissions funded. Title: American College of Clinical Pharmacy cardiovascular fellowship


31

Grant Support (cont'd): Sponsor: American College of Clinical Pharmacy Research Institute and Merck and Co. Amount: $22,500 Date: July, 1997 – June, 1998 Role: Principal Investigator/Preceptor Title: Fellowship in cardiovascular pharmacotherapy Sponsor: Hoechst Marion Roussel Amount: $48,000 Date: July, 1996 – June, 1998 Role: Principal Investigator/Preceptor Title: Erythromycin-induced QTc interval prolongation and increased QT interval dispersion: incidence, risk factors, and relationship with serum erythromycin concentrations. Award: Small Projects Grant Sponsor: Henry Ford Hospital Amount: $10,000 Date: 1995-1996 Role: Principal Investigator Funding rate: 12 of 24 submissions funded. Title: Efficacy of intravenous diltiazem compared to digoxin for the management of post-surgical atrial fibrillation Sponsor: Marion-Merrell Dow, Inc Amount: $69,535 Date: 1994-1995 Role: Principal Investigator Title: Fellowship in cardiovascular pharmacotherapy Sponsor: Marion-Merrell Dow, Inc. Amount: $38,320 Date: July, 1994 - June, 1996 Role: Principal Investigator/Preceptor Title: Inhibition of N-acetylation of procainamide by para-aminobenzoic acid in humans. Award: New Investigator Award Sponsor: American Association of Colleges of Pharmacy Amount: $7,500


32

Grant Support (cont'd): Date: 1993-1994 Role: Principal Investigator Title: Inhibition of N-acetylation of procainamide by para-aminobenzoic acid in humans Award: Small Projects Grant Sponsor: Henry Ford Hospital Amount: $10,000 Date: 1993-1994 Role: Principal Investigator Funding rate: 5 of 23 submissions funded. Title: Pathophysiology of atrial fibrillation in a dog model of congestive heart failure Award: Institutional Research Support Grant Sponsor: Henry Ford Hospital Amount: $150,000 Date: 1993-1994 Role: Co- Investigator Title: Neurohumoral pharmacodynamics of cocaine Award: Supplemental Research Equipment Grant Sponsor: Wayne State University Amount: $6,850 Date: 1993-1994 Role: Co-Investigator Title: Pharmacokinetics of procainamide in patients with congestive heart failure Award: Small Projects Grant Sponsor: Henry Ford Hospital Amount: $10,000 Date: 1993-1994 Role: Principal Investigator Funding rate: 6 of 24 submissions funded. Title: The effect of cocaine on ventricular fibrillation threshold in dogs Award: Small Projects Grant Sponsor: Henry Ford Hospital Amount: $10,000 Date: 1992-1993


33

Grant Support (cont'd): Role: Principal Investigator Funding rate: 6 of 24 submissions funded. Title: Electrophysiologic testing as a guide to antiarrhythmic therapy for ventricular tachyarrhythmias - predictors of response to antiarrhythmic therapy, recurrence of arrhythmias, and sudden cardiac death Sponsor: Hartford Hospital Intramural Research Grant Amount: $25,000 Date: 1989-1990 Role: Co-Principal Investigator Post-Doctoral Fellows Trained 1. I. Desmond Padhi, PharmD, 1994-1996. Current position: Vice President, Medical

Sciences, Amgen, Inc., Thousand Oaks, CA. 2. Neeta B. Amin, PharmD, 1996-1998. Current position: Clinical Lead, CVMED Research

Unit, Pfizer Worldwide Research and Development, Cambridge, MA. 3. Sam Rasty, PharmD, MPH, BCPS, 1998-2000. Current position: Associate Professor,

Department of Clinical and Administrative Sciences, College of Pharmacy, California Northstate University, Elk Grove, CA.

4. Kwadwo Amankwa, PharmD, 2000-2002. Current position: Assistant Professor,

Department of Clinical and Administrative Sciences, School of Pharmacy, College of Notre Dame of Maryland, Baltimore, MD.

5. Beth L. (Cariera) Twydell, PharmD, 2003-2004. Current position: Pharmacist, Highland

Hospital, Strong Health, Rochester, NY. Graduate Students Mentored as Major Professor 2009- 2012 Noha Mourad (Master’s degree) 2015 - present Elena Tomaselli (PhD) Graduate Student Service as Advisory Committee Member 2002-2005 Cindy Zhang (PhD)


34

Graduate Student Service as Advisory Committee Member 2011-2016 Ahmed Mohamed Abdelhady (PhD) 2008-2013 Ahmed Mohamed Nader (PhD) 2010-2015 Christina Chung (PhD) 2014-present Tyler Shugg (PhD) 2015-present Abdullah Assiri (PhD) 2018 – present Saugat Adhikari (PhD) Honors and Awards: 1983 Smith, Kline and French Award for Excellence in Clinical Pharmacy and Participation in University Life, presented by the Faculty of Pharmacy, University of Manitoba, and Smith, Kline and French 1983 Graduate Fellowship in Hospital Pharmacy, awarded by the

Canadian Foundation for the Advancement of Pharmacy (now the Canadian Foundation for Pharmacy) 1986 Fellowship in Professional Practice, awarded by the Canadian Foundation for Pharmacy 1987 Smith, Kline and French Scholarship for Postgraduate Education, awarded by the Canadian Society of Hospital Pharmacists and Smith, Kline and French 1993 New Investigator Award, American Association of Colleges of Pharmacy 1998 Elected Fellow of the American College of Clinical Pharmacy (FCCP) 2010 Excellence in Leadership Award, Indiana College of Clinical Pharmacy 2010 Elected Fellow of the American Pharmacists Association (FAPhA) 2010 Elected Fellow and Distinguished Practitioner and Fellow of the National

Academies of Practice (FNAP) 2011 Establishment of the annual Tisdale Pharmacy Professionalism Award by

the Indiana College of Clinical Pharmacy


35

Honors and Awards (cont’d): 2011 Elected Fellow of the American Heart Association (FAHA) 2015 Outstanding Paper of the Year Award, Cardiology Practice and Research

Network, American College of Clinical Pharmacy 2017 Russell R. Miller Award, American College of Clinical Pharmacy,

awarded for sustained contributions to the literature 2018 Elected Fellow of the American College of Cardiology (FACC) Teaching Awards: 1992 Preceptor of the Year, voted by the Wayne State University Doctor of Pharmacy class of 1992

1993 Preceptor of the Year, voted by the Wayne State University Doctor

of Pharmacy class of 1993 1993 Instructor of the Year, voted by the Wayne State University Doctor

of Pharmacy class of 1994 1994 Preceptor of the Year, voted by the Wayne State University Doctor

of Pharmacy class of 1994 1994 Instructor of the Year, voted by the Wayne State University Doctor

of Pharmacy class of 1995 1996 Excellence in Teaching Award, College of Pharmacy & Allied

Health Professions, Wayne State University 1998 Instructor of the Year, voted by the Wayne State University Bachelor of Science in Pharmacy class of 1999 1999 Instructor of the Year, voted by the Wayne State University Bachelor of Science in Pharmacy class of 2000 1999 Excellence in Teaching Award, College of Pharmacy & Allied

Health Professions, Wayne State University


36

Teaching Awards (cont’d): 2005 Faculty Preceptor of the Year Award, College of Pharmacy, Purdue

University 2013 Dr. Aziz Outstanding Teacher of the Year Award, College of Pharmacy,

Purdue University Teaching Activities at Purdue University Courses Coordinated Graduate Seminar – Focus on Cardiac Electrophysiology (CLPH 69600) 2015 Courses Co-coordinated Pathophysiology & Therapeutics II (CLPH 872) 2005-2008 Courses Taught Integrated Laboratory V (PHRM 403) 2002 - 2013 Principles of Literature Evaluation and Drug Information (CLPH 567) 2003 - 2006 Pathophysiology & Therapeutics II (CLPH 872) 2003 – 2013 Professional Seminar (CLPH 490s) 2006 Introduction to Clinical Research (CLPH 490N) 2007-2012 Nursing Pharmacology (NUR 502) 2008 – present Pharmacy Practice Laboratory (PHRM 821) 2015 - present Integrated Pharmacotherapy III (PHRM 84500) 2014 - present Experiential Teaching APPE in Adult Internal Medicine 2003 – 2013 Doctor of Pharmacy program 12 students per year, 4 week rotations APPE in Cardiovascular Research 2003 – present Doctor of Pharmacy program 1-2 students per year, 4 week rotation Teaching Activities at Indiana University Clinical Pharmacology Journal Club 2002 - present Clinical Therapeutics for Physician Assistants (K504) 2014 - present


37

Teaching Activities at Wayne State University Experiential Teaching – Advanced Practice Clerkships Clerkship in Internal Medicine 1999-2002 Clerkship in Cardiovascular Research 1990-2002 Courses Developed Advanced Therapeutic Problem Solving I (PPR 6160) – led a small team that developed this 5 credit hour course in 1999 for the new entry-level PharmD program. Course is student-directed & problem-based, and teaches a system for identification and resolution of drug-related problems. Advanced Therapeutic Problem Solving II (PPR 6160) – led a small team that developed this 5 credit hour course in 1999 for the new entry-level PharmD program. Course is student-directed & problem-based, and reinforces the system for identification and resolution of drug-related problems taught in Advanced Therapeutic Problem Solving I. Cardiovascular Pharmacotherapeutics (PHA 4150) - co-developed (with Dr. Randall Commissaris), this multidisciplinary course in 1994, incorporating pathophysiology, medicinal chemistry, pharmacology, pharmacokinetics, and clinical therapeutics Courses Coordinated Advanced Therapeutic Problem Solving I (PPR 6160) 1999-2003 Advanced Therapeutic Problem Solving II (PPR 6160) 2000 Cardiovascular Disease Processes and Therapeutics (PPR 712) (4 credit hours) 1991-1998 Cardiovascular Pharmacotherapy (PPR 450) (2 credit hours) 1991-1993 Courses Taught Advanced Therapeutic Problem Solving I (PPR 6160) (5 credit hours) 1999 Cardiovascular Disease Processes and Therapeutics (PPR 712) (4 credit hours) 1990-1998 Cardiovascular Pharmacotherapy (PPR 450) (2 credit hours) 1990-1993 Cardiovascular Pharmacotherapeutics (PHA 4150) (2 credit hours) 1994-2002 Advanced Pharmacokinetics (PPR 7670) (2 credit hours) 1990-2002 Drug-Induced Diseases (PPR 6110) (2 credit hours) 1996-2002 Orientation to Externship (PPR 5100) 1 credit hour 1994-1999 Directed Study (PPR 5900), 2 credit hours 1990-2002


38

Teaching Activities at Wayne State University (cont’d): Didactic Teaching Contact Hours 2001-2002: 23 hours 2000-2001: 23 hours 1999-2000: 82 hours 1992-1999: 60 hours per year Experiential Teaching Clerkship in Cardiovascular Pharmacotherapy 2001-2002 Entry-level Doctor of Pharmacy program 4 students, 6-week rotations Clerkship in Neurovascular Pharmacotherapy 2001-2002 Entry-level Doctor of Pharmacy program 4 students, 6-week rotations Clerkship in Cardiovascular Pharmacotherapy (PPR 726) 1990-2000 Post-B.S. Doctor of Pharmacy program Average of 6-9 students per year, 4-week rotations Undergraduate Hospital Externship (PPR 5120) 1991-2002 B.S. program Average of 8-10 students per year, taught in a total of two 6-week rotations (24 weeks per year) Clerkship in Cardiovascular Research 1990-2000 Post-B.S. Doctor of Pharmacy program Average of 1 student every other year, 4-week rotation Committee Service at Purdue University Membership on University Committees Search Committee, Dean, College of Pharmacy, Nursing 2006 & Health Sciences Committee on Research Integrity 2009-present Review Committee for Dean of the College of Pharmacy 2011 Grievance Committee 2011 Provost’s Task Force on Promotion and Tenure 2011 – 2013 Academic Advisory Committee, Regenstrief Center for 2014 – present Healthcare Engineering


39

Committee Service at Purdue University (cont’d): College of Pharmacy Committees Chaired Search Committee, Pharmacokinetics/Pharmacodynamics position 2004 Search Committee, Anderson Endowed Chair in Clinical Pharmacology 2006-2007 Position Strategic Planning Committee 2007-2008 Subcommittee, College of Pharmacy ACPE Self-Study, 2010 - 2011 Standards 1-3, Mission, Planning, & Evaluation Executive Committee 2012 – 2014 Faculty Awards Nominations Committee 2015 -present Membership on College of Pharmacy Committees Awards Nominations Committee 2003 - present Graduate Affairs Committee 2003 - present Therapeutics Committee 2003 - present Graduate Recruitment Subcommittee 2003 – present Combined PharmD/MBA degree committee 2003 – 2005 Tuition Task Force 2003 ACPE self-study committee, faculty section 2005 Promotion and Tenure Committee 2005–2008,

2012-2016 Grievance Committee 2006 – 2008 Mosaic for Educational Equity – Graduate Student Recruitment & 2006-2007 Retention subcommittee Faculty Scholars Selection Committee 2011 – present Executive Committee 2012 – 2014 Murphy Award Committee 2013 – present Task Force on Communications and Teamwork 2016 Member, Strategic Area Task Force on Research & Innovation 2017 – present Membership on Department of Pharmacy Practice Committees Primary Promotion and Tenure Committee 2002 – present Search Committee, Endowed Chair for Medication Safety 2007 – 2008 Journal Ranking Committee (Chair) 2006 - 2012 Department of Pharmacy Practice Executive Committee 2008 – 2012 Annual Review Report Committee 2014 - present Department of Pharmacy Practice Awards Committee (Chair) 2015 – present


40

Committee Service at Indiana University Member, Advisory Committee, General Clinical Research 2004 – 2007 Center (GCRC) Member, Executive Committee, Personalized Therapeutics 2008 – present Group, Division of Clinical Pharmacology Member, Phase 1 Unit Advisory Committee, Indiana Clinical 2013 - present Research Center Committee Service at Wayne State University Committees Chaired Curriculum Committee 2001-2002 Doctor of Pharmacy Program Committee 1996-1999 Membership on University Committees Search Committee for the Dean, College of Pharmacy & Allied 2000-2001 Health Professions University Research Grant Program 2000-2001 Committee to Review the College of Pharmacy & Allied Health 1998 Professions Membership on College of Pharmacy & Allied Health Profession Committees Undergraduate Externship Task Force Subcommittee 1991-2002 Admissions and Honors Committee 1992–1993,2000-2002 Unit Select Salary Committee 1995-2002 Ad-hoc Committee for Bylaws Revision 1995 - 2002 Promotion & Tenure Committee 1996–1999, 2001-2002 Member, Standing Hearing Panel, College of Pharmacy 1997-2002 Experiential Subcommittee (of the Curriculum Committee) 1999-2001 Committee on Academic and Professional Progress 1993-1995, 1996-1998 Pre-professional Subcommittee of the Curriculum Committee 1995 – 1998 Doctor of Pharmacy Program Committee 1990-1999 Doctor of Pharmacy Program Admissions Committee 1991-1993 American Association of Colleges of Pharmacy Delegate 1995-1996 Awards/Scholarships Subcommittee 1991-1992 Library Committee 1991-1992


41

Faculty Advisor at Wayne State University: Faculty advisor to the class of 1998 Faculty advisor to the Alpha Chi Chapter, Rho Chi Pharmacy Honors Society (1998 - 2002) Membership in Professional Organizations: 1983 - 1994, 1999 - present Canadian Society of Hospital Pharmacists 1986 - present American Society of Health-Systems Pharmacists 1988 - present American College of Clinical Pharmacy 1990 - 1997 American College of Clinical Pharmacology 1990 - 2010 American Society For Clinical Pharmacology and Therapeutics 1990 - 2003 Southeastern Michigan Society of Hospital Pharmacists 1991 - present American Association of Colleges of Pharmacy Membership in Professional Organizations (cont’d): 1994 - present American Heart Association (Clinical Cardiology & Basic

Cardiovascular Sciences Councils) 1997 - 2002 Michigan Pharmacists' Association 1998 - present American Pharmacists Association 2000 - 2010 Heart Failure Society of America 2003 – present Indiana Pharmacists Alliance 2015-present Heart Rhythm Society 2003 – present Indiana Society of Health-System Pharmacists 2013 – present American College of Cardiology Offices Held in Professional Organizations 2001 – 2004 Member, Board of Regents, American College of Clinical

Pharmacy 2005 - 2007 Member-at-Large, Clinical Sciences Section, Academy of

Pharmaceutical Research & Science, American Pharmacists Association

2007 – 2008 Chair-Elect, Clinical Sciences Section, Academy of

Pharmaceutical Research & Science, American Pharmacists Association 2008 – 2009 Chair, Clinical Sciences Section, Academy of Pharmaceutical


42

Offices Held in Professional Organizations (cont’d):

Research & Science, American Pharmacists Association

2008 - 2009 President-Elect, American College of Clinical Pharmacy 2009 – 2010 President, American College of Clinical Pharmacy 2010 – 2011 Past-President, American College of Clinical Pharmacy Committee Appointments: Professional Organizations: 1984 - 1986 Member, Continuing Education Committee Manitoba Pharmaceutical Association 1991 - 1994 Member, Publications Committee,

American College of Clinical Pharmacy 1991 - 1998 Member, State Healthcare Site Committee,

American Heart Association of Michigan 1991 - 1998 Member, Professional Education Committee

American Heart Association of Michigan 1992 - 1994 Member, Midwestern Regional Pharmacy Cholesterol Council 1994 - 1997 Appointed to American Society of Hospital Pharmacists

expert panel for development of guidelines for the use of angiotensin converting enzyme inhibitors in congestive

heart failure

1994 - 1997 Appointed to Cardiology Item Writing Panel of the Specialty Council on Pharmacotherapy of the Board of

Pharmacy Specialties 1996 - 1998 Member, Program Committee American Heart Association of Michigan 2000 - 2002 Member, Public Affairs Committee

Michigan Society of Health-System Pharmacists


43

Committee Appointments: Professional Organizations (cont’d): 2001 - 2002 Member, Public Affairs Committee Michigan Pharmacists Association

2000 - 2006 Nonspecialist Member, Board of Pharmacy Specialties Specialty Council on Psychiatric Pharmacy 2003 – 2004 Member, Nominating Committee American Society for Clinical Pharmacology & Therapeutics

2007 – 2009 Member, Education Committee, Academy of Pharmaceutical

Research & Science, American Pharmacists Association 2007 – 2009 Member, Policy Committee, Academy of Pharmaceutical Research

& Science, American Pharmacists Association 2007 – 2009 Member, Governance/Membership Committee, Academy of

Pharmaceutical Research & Science, American Pharmacists Association

2008 – 2009 Member, Nominating Committee, Academy of Pharmaceutical

Research & Science, American Pharmacists Association 2011 – 2012 Member, Awards Committee, American College of Clinical

Pharmacy 2012 Member, Scientific Classifications Review Task Force, American

Heart Association 2014 – 2015 Member, Membership Working Group, Cardiovascular Team

Council, American College of Cardiology 2014 – 2015 Member, Program Committee, 2015 ACCP Global Conference on

Clinical Pharmacy, American College of Clinical Pharmacy 2014 – present Member, Clinical Pharmacology Committee, Clinical Cardiology

Council, American Heart Association 2015 – 2018 Member, Lifelong Learning Committee (formerly the Professional

Education Committee), American Heart Association/American


44

Committee Appointments: Professional Organizations (cont’d):

Stroke Association 2015 – 2017 Cardiovascular Team Communication Work Group, American

College of Cardiology 2015 – 2016 Member, Presidential Task Force, American College of Clinical

Pharmacy 2017 – present Member, Electrophysiology Section Leadership Council,

American College of Cardiology 2017 – present Member, Paul F. Parker medal Selection Committee, American

College of Clinical Pharmacy Committee Chairmanships in Professional Organizations 1984 - 1985 Associate Chair, Education Committee, Canadian Society of

Hospital Pharmacists (Manitoba Branch)

1985 - 1986 Chairman, Education Committee, Canadian Society of Hospital Pharmacists (Manitoba Branch)

1993 - 1994 Chairman, Publications Committee,

American College of Clinical Pharmacy 1993 - 1995 Chairman, Professional Education Committee,

American Heart Association of Michigan 1995-1997 Chairman, Research Affairs Committee,

American College of Clinical Pharmacy

1997-1999 Chairman, Program Committee, 1999 Annual Meeting American College of Clinical Pharmacy

1999 - 2000 Chairman, Constitution & Bylaws Committee,

American College of Clinical Pharmacy 2003 – 2006 Vice-Chair, Cardiology & Pulmonary Scientific Section,

American Society for Clinical Pharmacology & Therapeutics


45

Committee Chairmanships in Professional Organizations (cont’d): 2008 – 2009 Chair, Education Committee, Academy of Pharmaceutical

Research & Science, American Pharmacists Association 2013 – 2014 Chair, Presidential Task Force, American College of Clinical

Pharmacy 2017 – present Chair, Nominations Committee, American College of Clinical

Pharmacy Journal Editorship 1999 - 2018 Associate Editor, Canadian Journal of Hospital Pharmacy 2015 – present Scientific Editor, Pharmacotherapy Editorial and Other Board Membership 1999 - 2003 Pharmacotherapy Self-Assessment Program (PSAP), 4th Ed. 1999 - 2004 Journal of Informed Pharmacotherapy 2000 – 2003, 2013 - 2016 Journal of the American Pharmacists Association 2000 - 2015 Pharmacotherapy 2014 – present Member, Scientific Advisory Board, CredibleMeds.org 2017 – present Member, Board of Directors, AZCERT 2017 – present Member, Editorial Board, Trends in Cardiovascular Medicine Abstract reviewer 1995 - 2017 American College of Clinical Pharmacy Annual Meeting 2014 - 2017 American Heart Association Annual Scientific Sessions 2015-2016 American College of Clinical Pharmacy Virtual Poster Symposium Reviewer for the Following Journals: 1990 Sports Medicine 1990 - 1993 Clinical Pharmacy 1992 - present American Journal of Health-Systems Pharmacy 1994 - present Canadian Journal of Hospital Pharmacy 1994 - present Annals of Pharmacotherapy 1996 - present Pharmacotherapy 1997 - present Journal of Managed Care Pharmacy


46

Reviewer for the Following Journals (cont’d): 1997 - present Journal of Pharmacy Technology 1999 American Heart Journal 2001 Clinical Infectious Diseases 2002 – present Clinical Pharmacology & Therapeutics 2002 – present Canadian Journal of Emergency Medicine 2003 – present American Journal of Pharmaceutical Education 2003 – present Critical Care Medicine 2005 – present American Journal of Managed Care 2006 – present Pharmaceutical Research 2006 – present Journal of Pharmacy & Pharmacology 2006 – present Journal of Pharmacological and Toxicological Methods 2006 – present Annals of Epidemiology 2006 – present Biochemical Pharmacology 2007 – present Quarterly Journal of Medicine 2007 – present Therapeutics and Clinical Risk Management 2007 – present Journal of Pharmaceutical Sciences 2007 – present American Journal of Hypertension 2007 – present Acta Pharmacologica Sinica 2007 – present Journal of the American Pharmacists Association 2008 – present Journal of Clinical Pharmacology 2009 – present Expert Opinion on Drug Safety 2009 – present Clinical Pharmacokinetics 2009 – present Heart 2010 – present Current Drug Therapy 2010 – present Core Evidence 2010 – present British Journal of Clinical Pharmacology 2010 – present Journal of Molecular and Cellular Cardiology 2011 – present Journal of Cardiac Failure 2011 – present Journal of Cardiothoracic Surgery 2011 – present Circulation Arrhythmia Electrophysiology 2011 – present Annals of Internal Medicine 2011 – present British Journal of Pharmacology 2013 – present Journal of Psychopharmacology 2013 – present Annals of Medicine 2013 – present European Medical Journal – Cardiology 2014 – present Drugs and Aging 2014 – present Annals of Surgery 2014 – present Drugs in R&D 2014 – present Journal of Clinical Psychopharmacology


47

Reviewer for the Following Journals (cont’d): 2014 – present PLOS One 2014 – present Circulation 2015 – present American Journal of Cardiology 2015 – present Pharmacoepidemiology and Drug Safety 2016 – present Basic & Clinical Pharmacology & Toxicology 2016 – present International Journal of Clinical Pharmacy 2017 – present Clinical Transplantation 2017 – present Trends in Cardiovascular Medicine 2017 – present Circulation: Heart Failure 2017 – present Canadian Journal of Psychiatry 2017 – present New England Journal of Medicine 2017 – present JAMA Internal Medicine 2018 – present BMJ Open Reviewer for the Following Chapters, Guidelines and Position Statements:

1993 Lidocaine. In: Murphy J, ed. Clinical Pharmacokinetics Pocket Reference. 1994 Tachycardias. In: American College of Clinical Pharmacy.

Pharmacotherapy Self-Assessment Program, Cardiovascular Module, 2nd Ed.

1994 The Heart and Myocardial Infarction. In: American Society of Health-Systems Pharmacists. Basic Skills in Interpreting Laboratory Data 1995 Allergic Diseases: Atopic Dermatitis, Anaphylaxis, Drug Allergy. In: American College of Clinical Pharmacy. Pharmacotherapy Self-Assessment Program, Immunology/ Endocrinology Module, 2nd Ed. 1997 Cardiopulmonary Resuscitation - Focus on Drug Therapy. In: American College of Clinical Pharmacy. Pharmacotherapy Self- Assessment Program, Cardiovascular Module, 3rd Ed. 1997 Management of Systolic Heart Failure. In: American Pharmaceutical Association. APhA Guide to Drug Treatment


48

Reviewer for the Following Chapters, Guidelines and Position Statements (cont’d): Protocols. 1999 Quinidine. In: Murphy J, ed. Clinical Pharmacokinetics Pocket Reference, 2nd Ed. 2000 Bell D. Pharmacological Aspects to Exercise. In: Ehrman JK, et al (eds). Textbook of Clinical Exercise Physiology. 2001 Southworth MR, Bauman JL. Cardiology Specialty Pharmacy Practice. In: DiPiro JT, et al (eds). Encyclopedia of Clinical Pharmacy. 2003 Cheng J. Life-Threatening Arrhythmias. In: American College of Clinical Pharmacy. Pharmacotherapy Self-Assessment Program, Cardiology Module, 5th Ed. 2003 Humma L. Cardiovascular. In: American College of Clinical Pharmacy. Pharmacogenomic Applications in Patient Care. 2004 American Society of Health-Systems Pharmacists. ASHP Therapeutic Position Statement on the Use of Aspirin for Prevention of Coronary Heart Disease. 2005 Omnicare Geriatric Pharmaceutical Care Guidelines 2011 Engle JP. Professional Networking and Career Advancement. In:

Murphy J, ed. Resident Survival Guide. Lenexa, KS; American College of Clinical Pharmacy: 2011.

2012 Haines S. Define (and Re-Define) Your Goals. In: Bauman JL, ed.

The ACCP Field Guide to Becoming a Standout Pharmacy Residency Candidate. Lenexa, KS; American College of Clinical Pharmacy: 2012.

2016 Haines S. Define (and Re-Define) Your Goals. In: Bauman JL, ed.

The ACCP Field Guide to Becoming a Standout Pharmacy Residency Candidate, 2nd ed. Lenexa, KS; American College of Clinical Pharmacy: 2016.


49

Reviewer for the Following Chapters, Guidelines and Position Statements (cont’d): 2017 Peer reviewer for the 2017 American College of

Cardiology/American Heart Association/Heart Rhythm Society Guideline for Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death

2018 Peer reviewer for 2018 American College of Cardiology/American

Heart Association/Heart Rhythm Society Focused Update of the 2014 American College of Cardiology Foundation/American Heart Association/Heart Rhythm Society Guideline for the Management of Patients with Atrial Fibrillation

2018 Peer reviewer for the 2018 American Psychiatric Association

(APA) Resource Document on QTc Prolongation and Psychotropic Medications

Study Section membership 2014 Special Emphasis Panel, NIH, National Institute of Allergy and

Infectious Diseases, Phase I Clinical Trial Unit for Therapeutics against Infectious Diseases 2016 Department of Defense (DOD) Center for Peer Review and

Science Management, Peer Reviewed Medicine Research Program Other grant reviews: 1999, 2000 American College of Clinical Pharmacy Research Grant Program, Cardiovascular Fellowship 2001 U.S. Civilian Research & Development Foundation Cooperative Grants Program 2005, 2006 American College of Clinical Pharmacy Cardiology Minisabbatical

program 2006 American College of Clinical Pharmacy Investigator Development Grant Program 2008 American College of Clinical Pharmacy Grants and Fellowships


50

Selection Committee

Presentations National/International Meetings 1. "Digoxin for heart failure: obsolete or born again?" The fourth Canadian Symposium of the American College of Clinical Pharmacy, Banff, Alberta, Canada, March 20, 1992. 2. "Antiarrhythmic drugs in the '90's". Presented at the Professional Practice Conference of the Canadian Society of Hospital Pharmacists, Toronto, Ontario, Canada, February 3, 1993. 3. "Safety of intravenous antiarrhythmic agents." Exhibitors' Theater, American Society of

Hospital Pharmacists Midyear Clinical Meeting, Miami Beach, FL, December 5, 1994. 4. "Round table discussions - Cardiac arrhythmias, congestive heart failure, & hypertension." Annual Meeting of the Canadian College of Clinical Pharmacy, London, Ontario, Canada, September 30, 1995. 5. "Contemporary approaches to treatment of heart failure - how far have we progressed?" Annual Meeting of the American Society of Consultant Pharmacists, Nashville,

Tennessee, November 16, 1996. 6. "Contemporary treatment of heart failure - what have we learned?" American Society of

Health-System Pharmacists Midyear Clinical Meeting, New Orleans, Louisiana, December 9, 1996.

7. "Antiplatelet therapy in atherosclerotic disease: review and update of efficacy studies." American Society of Health-Systems Pharmacists Midyear Clinical Meeting, Atlanta,

Georgia, December 7, 1997. 8. "Ventricular rate control in atrial fibrillation." American Society of Health-Systems Pharmacists Midyear Clinical Meeting, Atlanta, Georgia, December 8, 1997. 9. "Should antiarrhythmic agents be first-line therapy to prevent sudden cardiac death?" American College of Clinical Pharmacy Spring Practice and Research Forum, Palm

Springs, California, April 8, 1998. 10. "Contemporary treatment of heart failure - what have we learned?" Annual meeting of the

Academy of Managed Care Pharmacy, Philadelphia, PA, May 2, 1998.


51

Presentations (National/International Meetings) cont'd: 11. "Should beta-blockers be first-line agents for the management of congestive heart

failure?" American Society of Health-Systems Pharmacists Midyear Clinical Meeting, Las Vegas, NV, December 9, 1998.

12. "Congestive heart failure: physical assessment." American Society of Health-Systems Pharmacists Midyear Clinical Meeting, Las Vegas, NV, December 10, 1998. 13. "Post-CABG atrial fibrillation: an ounce of prevention?" Annual meeting of the American College of Clinical Pharmacy, Kansas City, MO, October 23, 1999. 14. Advanced cardiac life support: evidence for current treatment guidelines. Annual meeting of the American Society of Health-System Pharmacists, Philadelphia, PA, June 7, 2000. 15. "Being a reviewer: how to critically review a journal manuscript." Meet the Experts Luncheon, 21st Annual Meeting of the American College of Clinical Pharmacy, Los Angeles, CA, November 7, 2000. 16. "The electrical system in heart failure: to treat or not to treat." American Society of

Health-Systems Pharmacists Midyear Clinical Meeting, Las Vegas, NV, December 4, 2000. 17. “The implantable defibrillator is first line therapy in post-MI patients with nonsustained ventricular tachycardia and left ventricular dysfunction.” American College of Clinical Pharmacy Spring Research and Practice Forum, Salt Lake City, UT, April 24, 2001. 18. “Conservative treatment strategies in atrial fibrillation.” Exhibitors’ Theater presented at the 22nd Annual Meeting of the American College of Clinical Pharmacy, Tampa FL, October 21, 2001. 19. “Review of the new ACLS guidelines.” Exhibitors’ Theater presented at the 22nd Annual Meeting of the American College of Clinical Pharmacy, Tampa FL, October 22, 2001. 20. “When should conservative treatment strategies be used in atrial fibrillation?” Exhibitors’ Theater presented at the American Society of Health Systems Pharmacists Midyear Clinical Meeting, New Orleans LA, December 4, 2001. 21. “Be still my beating heart: culprits and mechanisms of drug-induced arrhythmias.” Professional Practice Conference of the Canadian Society of Hospital Pharmacists, Toronto, Ontario, Canada, February 4, 2002.


52

Presentations (National/International Meetings) cont'd: 22. “The prolonged QT interval – is it real?” Annual Meeting of the American Society of Consultant Pharmacists, Las Vegas, NV, May 15 2002. 23. “Pharmacology of current and new antiarrhythmic agents.” Presented at a satellite symposium entitled, “Applying Best Practices in Atrial Fibrillation” at the Annual Meeting of the Academy of Managed Care Pharmacists, Baltimore, MD, October 14, 2004. 24. "Debate: Con: Hypertension should be not treated aggressively in very elderly patients." 25th Annual Meeting of the American College of Clinical Pharmacy, Dallas, TX, October 26, 2004. 25. "Selecting antithrombotic therapy for acute coronary syndromes." 25th Annual Meeting of

the American College of Clinical Pharmacy, Dallas, TX, October 27, 2004. 26. "Debate: Pro: Long-term dual antiplatelet therapy should is warranted in most patients with cardiovascular disease." 25th Annual Meeting of the American College of Clinical

Pharmacy, Dallas, TX, October 27, 2004. 27. “Getting pharmacists involved on code blue teams.” 26th Annual Meeting of the

American College of Clinical Pharmacy, San Francisco, CA, October 26, 2005. 28. “Drug-induced cutaneous reactions.” American Society of Health-Systems Pharmacists Midyear Clinical Meeting, Las Vegas, NV, December 5, 2005. 29. “Cardiovascular risk reduction in the elderly.” American Society of Health-Systems Pharmacists Midyear Clinical Meeting, Las Vegas, NV, December 6, 2005. 30. “Are we there yet? Antiarrhythmic pharmacotherapies in development.” Presented at a symposium entitled “Rhythm control in atrial fibrillation: mapping current and emerging pharmacotherapies.” 27th Annual Meeting of the American College of Clinical Pharmacy, St. Louis, MO, October 25, 2006. 31. “Debate: Amiodarone should be included in the Beers criteria for potentially

inappropriate medication use in the elderly.” 28th Annual Meeting of the American College of Clinical Pharmacy, Denver, CO, October 15, 2007.

32. “Antiarrhythmic overview: the good, the bad, and the balance.” American Society of

Health-Systems Pharmacists Midyear Clinical Meeting, Las Vegas, NV, December 5,


53

Presentations (National/International Meetings) cont'd:

2007. 33. “Antiarrhythmic drug therapy and management of arrhythmias.” Presented at the

symposium entitled, “3rd Annual Clinical Pharmacology in the Management of

Cardiovascular Disease,” American College of Cardiology Annual Scientific Sessions, Chicago, IL, March 29, 2008.

34. “Addressing reviewers’ comments.” Presented as part of a curricular track entitled,

“Improving Scholarly Productivity,” American College of Clinical Pharmacy Spring Practice & Research Forum, Phoenix, AZ, April 9, 2008.

35. “Late-Breakers, cardiovascular & critical Care therapeutics.” Presented at the 29th Annual

Meeting of the American College of Clinical Pharmacy, Louisville, KY, October 20, 2008.

36. “Debate: Hypertension should not be treated aggressively in the very old.” Presented at

the 29th Annual Meeting of the American College of Clinical Pharmacy, Louisville, KY, October 20, 2008.

37. “Prevention and management of antiarrhythmic drug toxicity.” Presented at the 43rd

American Society of Health-Systems Pharmacists Midyear Clinical Meeting, Orlando, FL, December 10, 2008.

38. “Amiodarone for prevention of atrial fibrillation following pulmonary resection: results

of a prospective randomized trial.” Presented at the 45th Annual Meeting of the Society of Thoracic Surgeons, San Francisco, CA, January 27, 2009.

39. “Management of peripheral arterial disease.” Presented at the Annual Meeting of the American Pharmacists Association, San Antonio, TX, April 5, 2009.

40. “Drug therapy management of patients with atrial fibrillation and other common arrhythmias.” Canadian Society of Hospital Pharmacists Summer Educational Sessions,

Winnipeg, Manitoba, Canada, August 10 & 11, 2009. 41. “First do no harm. Detection, prevention and management of drug-induced diseases.”

Canadian Society of Hospital Pharmacists Summer Educational Sessions, Winnipeg, Manitoba, Canada, August 10, 2009.


54

Presentations (National/International Meetings) cont'd: 42. “Medication safety: the unfulfilled promise.” Asian Conference on Clinical Pharmacy,

Seoul, Korea, September 27, 2009. 43. “Physiological changes associated with aging and age-related diseases.” Annual Meeting

of the American Association of Pharmaceutical Scientists, Los Angeles, CA, November 11, 2009.

44. “Prevention, detection and management of drug-induced diseases.” Qatar Health

Congress, Doha, Qatar, December 13, 2009. 45. “Antiarrhythmic drug therapy and management of arrhythmias.” Qatar Health Congress,

Doha, Qatar, December 14, 2009. 46. “The role of clinical pharmacy in shaping cardiovascular pharmacotherapy.” Keynote

address, 1st International Cardiovascular Pharmacotherapy Conference, Riyadh, Saudi Arabia, January 11, 2010.

47. “Evaluation, diagnosis and treatment of heart failure: the optimal drug therapy.” 1st

International Cardiovascular Pharmacotherapy Conference, Riyadh, Saudi Arabia, January 12, 2010.

48. “Pharmacological therapy for atrial fibrillation: a practical approach and review of the

guidelines.” 1st International Cardiovascular Pharmacotherapy Conference, Riyadh, Saudi Arabia, January 13, 2010.

49. “Panel discussion – pharmacology of resistant hypertension.” 60th Annual Scientific

Sessions of the American College of Cardiology, New Orleans, Louisiana, April 2, 2011. 50. “Panel discussion – pharmacotherapy of atrial fibrillation.” 60th Annual Scientific

Sessions of the American College of Cardiology, New Orleans, Louisiana, April 2, 2011. 51. “Time to jam: keeping a good atrial rhythm and QTc.” Presented at the 46th American

Society of Health-Systems Pharmacists Midyear Clinical Meeting, New Orleans, Louisiana, December 4, 2011.

52. “Issues and controversies: professional integrity and conflict of interest,” panel member, 43rd Annual Canadian Society of Hospital Pharmacists Professional Practice Conference, Toronto, Ontario, Canada, February 7, 2012.


55

Presentations (National/International Meetings) cont'd: 53. “Antiarrhythmic drug safety: illusion, fantasy, and wishful thinking? Dronedarone and

other disappointments.” 43rd Annual Canadian Society of Hospital Pharmacists Professional Practice Conference, Toronto, Ontario, Canada, February 7, 2012.

54. “Pharmacologic considerations with antiarrhythmic drugs.” 61st Annual Scientific Sessions of the American College of Cardiology, Chicago, Illinois, March 24, 2012.

55. “Drug-induced cardiovascular diseases: prevention, detection and management.” 4th

National Conference on Drug Injury and Safe Drug Use, Beijing, China, May 18, 2012. 56. “Roundtable discussion – research.” American College of Clinical Pharmacy Annual

Meeting, Hollywood, FL, October 20, 2012. 57. “Monitoring and management of QT interval prolongation and torsades de pointes.”

Annual Scientific Sessions of the American Heart Association, Los Angeles, California, November 3, 2012.

58. “First do no harm: prevention, detection and management of drug-induced diseases.”

46th American Society of Health-System Pharmacists Midyear Clinical Meeting, Las Vegas, NV, December 4, 2012.

59. “Cardiovascular effects of noncardiovascular drugs (panel discussion).” 62st Annual

Scientific Sessions of the American College of Cardiology, San Francisco, CA, March 9, 2013.

60. “Roundtable discussion – research.” American College of Clinical Pharmacy Annual

Meeting, Albuquerque, NM, October 14, 2013. 61. “Roundtable discussion – research.” American College of Clinical Pharmacy Annual

Meeting, Austin, TX, October 13, 2014. 62. “Drug-induced QT interval prolongation in hospitalized patients: what’s a pharmacist to

do?” 46th Canadian Society of Hospital Pharmacists Professional Practice Conference, Toronto, Ontario, Canada, February 3, 2015.

63. “Roundtable discussion – research.” American College of Clinical Pharmacy Annual

Meeting, San Francisco, CA, October 18, 2015.


56

Presentations (National/International Meetings) cont'd: 64. “Roundtable discussion – serving as a reviewer for Pharmacotherapy.” American

College of Clinical Pharmacy Annual Meeting, San Francisco, CA, October 20, 2015. 65. “Preparing a manuscript for submission to a peer-reviewed journal.” American College of

Clinical Pharmacy Annual Meeting, San Francisco, CA, October 20, 2015. 66. “Strategies for ventricular rate control.” Presented in a session entitled “Applying recent

guidelines in the management of patients with atrial fibrillation” at the 50th American Society of Health-System Pharmacists Midyear Clinical Meeting, New Orleans, LA, December 9, 2015.

67. “Methods for reducing the risk of drug-induced QT interval prolongation.” Presented in a

session entitled, “Prevention and management of drug-induced QT interval prolongation and torsades de pointes: essential tips for pharmacists” at the 51st American Society of Health-System Pharmacists Midyear Clinical Meeting, Las Vegas, NV, December 7, 2016.

68. “Drug-induced cardiovascular diseases.” Presented in a session entitled, “Drug-induced

diseases: prevention, detection and management” at the 51st American Society of Health-System Pharmacists Midyear Clinical Meeting, Las Vegas, NV, December 7, 2016.

69. “Roundtable discussion – research & scholarship.” American College of Clinical

Pharmacy Annual Meeting, Phoenix, AZ, October 8, 2017. 70. “Mechanisms of cardiotoxicity: old vs new chemotherapeutic agents.” American Heart

Association Annual Scientific Sessions, Anaheim, CA, November 13, 2017. 71. “Guideline-based management of arrhythmic complications in heart failure.” Presented in

a session entitled, “Guideline-based management of heart failure and arrhythmic complications” 52nd American Society of Health-System Pharmacists Midyear Clinical Meeting, Orlando, FL, December 5, 2017.

72. “Arrhythmias.” Presented at the Cardiology Pharmacy Preparatory Review Course, at the

American College of Clinical Pharmacy Annual Updates in Therapeutics, Jacksonville, FL, February 18, 2018.

73. “Arrhythmias.” Presented at the American College of Clinical Pharmacy Cardiology

Pharmacy Preparatory Review Course, Pomona, CA, April 22, 2018.


57

Presentations (National/International Meetings) cont'd: 74. “QTc interval prolongation: clinical relevance, prevention and management.” Presented

at the Annual Meeting of the College of Psychiatric and Neurologic Pharmacists, Indianapolis, IN, April 24, 2018.

Presentations (State/Regional Meetings): 1. "Electrophysiologic evaluation of drugs for the treatment of ventricular arrhythmias." Michigan Pharmacists Association Interim Meeting, Dearborn, MI, February 10, 1991. 2. "The controversy regarding the efficacy of digoxin in patients with congestive heart

failure". Michigan Pharmacists Association Interim Meeting, Dearborn, MI, February 23, 1992. 3. "Digoxin for heart failure: obsolete or born again?" Presented at a cardiovascular symposium of the British Columbia Branch of the Canadian Society of Hospital Pharmacists, Vancouver, British Columbia, Canada, September 12, 1992. 4. "Antiarrhythmic drugs: the good, the bad, and the ugly". Presented at a course entitled, "Complications and Side Effects of Commonly Used Cardiovascular Drugs" at the 127th

Annual Meeting of the Michigan State Medical Society, Dearborn, MI, November 19, 1992.

5. "Adverse effects of antiarrhythmic agents". Michigan Pharmacists Association Interim

Meeting, Dearborn, MI, February 19, 1993. 6. "Current use of calcium channel blockers". Presented at the Annual Meeting of the Manitoba Pharmaceutical Association, Winnipeg, Manitoba, Canada, April 23, 1993. 7. "Current management of congestive heart failure. How can you mend a failing heart?" Presented at the annual meeting of the Michigan Society of Hospital Pharmacists, Livonia, MI, October 15, 1993. 8. "Current management of hypertension - the JNC-V recommendations". Michigan Pharmacists Association Interim Meeting, Dearborn, MI, February 18, 1994. 9. “Management of the post-myocardial infarction patient." Annual meeting of the Michigan Society of Hospital Pharmacists, Lansing, MI, October 20, 1994.


58

Presentations (State/Regional Meetings) cont'd: 10. "Be still my quivering heart: current management of common cardiac arrhythmias."

Annual Meeting of the Canadian Society of Hospital Pharmacists (Saskatchewan Branch), Saskatoon, Saskatchewan, Canada, October 22, 1994.

11. "An introduction to chronotherapy." Annual Meeting of the Wisconsin Pharmacists Association, Milwaukee, WI, August 17, 1996. 12. "Individualization of drug therapy for hypertension." Annual Convention and Exposition of the Michigan Pharmacists Association, Dearborn, MI, February 21, 1997. 13. "Pathophysiology and epidemiology of congestive heart failure." Annual Convention and

Exposition of the Michigan Pharmacists Association, Dearborn, MI, February 21, 1998. 14. "Efficacy and potential cost-effectiveness of the glycoprotein IIb/IIIa receptor inhibitors."

Fall Clinical Meeting of the New York State Chapter of the American College of Clinical Pharmacy, Albany, NY, October 9, 1998.

15. "Beta-blockers in congestive heart failure." Annual meeting of the Michigan Society of

Health-System Pharmacists, Lansing, MI, October 8, 1999. 16. "Management of adult pulseless ventricular tachycardia and ventricular fibrillation." Annual Convention and Exposition of the Michigan Pharmacists Association, Dearborn, MI, February 16, 2001. 17. "Dofetilide: a new antiarrhythmic agent with unique prescribing and distribution requirements." Annual Convention and Exposition of the Michigan Pharmacists Association, Dearborn, MI, February 16, 2001. 18. “Prevention and treatment of drug-induced arrhythmias.” Annual Convention and Exposition of the Michigan Pharmacists Association, Dearborn, MI, February 24, 2002. 19. “Hearts aflutter: pharmacotherapy of supraventricular and ventricular arrhythmias.”

Canadian Society of Hospital Pharmacists Western Branches 28th Annual Banff Seminar, Banff, Alberta, Canada, March 9, 2002. 20. “Management of adult pulseless VT and VF: the pharmacist’s role.” Annual Meeting of the Ohio Society of Health-System Pharmacists, Dublin, OH, May 10 2002. 21. “A case-based approach to the management of atrial fibrillation.” Iowa Pharmacy


59

Presentations (State/Regional Meetings) cont'd: Association 2003 Educational Expo, Des Moines, IA, January 18, 2003. 22. “Significant papers in cardiovascular pharmacotherapy.” Indiana College of Clinical Pharmacy, Indianapolis, IN, April 7, 2004. 23. “Reducing cardiac risk.” Kentucky Society of Health-Systems Pharmacists’ 2004 Fall

Meeting, Lexington, KY, September 24, 2004. 24. “Management of atherosclerosis.” Annual meeting of the Pharmacy Society of

Wisconsin, Madison, WI, September 16, 2005. 25. “First do no harm: detection and management of drug-induced diseases.” Iowa

Pharmacists Association Educational Expo, Des Moines, IA, January 27, 2008. 26. “Drug-drug interactions and polypharmacy.” Indiana Geriatrics Society Annual Fall

Conference, Indianapolis, IN, October 22, 2010. 27. “Board certification for pharmacists – desirable, necessary, or irrelevant?” Combined

Annual meetings of the Nevada Society of Health-System Pharmacists and the California Society of Health-System Pharmacists, Las Vegas, NV, October 19, 2012.

28. “Pharmacology update – new on the market and does it work?” Annual meeting of

Indiana Chapter of the American College of Cardiology, Indianapolis, IN, October 18, 2014.

29. “The QT interval and drugs that prolong it – what do pharmacists need to know?” The

Annual Dal Refresher, Pharmacy Association of Nova Scotia, Oak Island, Nova Scotia, Canada, September 25, 2015.

30. “Evaluating your patient for drug-induced diseases.” The Annual Dal Refresher,

Pharmacy Association of Nova Scotia, Oak Island, Nova Scotia, Canada, September 26, 2015.

31. “Reducing the risk of drug-induced QT interval prolongation,” 5th Annual Indiana CTSI

Symposium on Disease and Therapeutic Response Modeling, Indianapolis, IN, November 5, 2015.


60

Presentations as Invited Professor 1. "Cardiac arrhythmias and antiarrhythmic agents." Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, British Columbia, Canada, October 11, 1994. 2. "Evidence against direct proarrhythmia associated with cocaine." Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, British Columbia, Canada, October 11, 1994. 3. "Management of supraventricular arrhythmias." Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, British Columbia, Canada, October 13, 1994. 4. "Management of ventricular arrhythmias." Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, British Columbia, Canada, October 14, 1994. 5. "Improving the safety and antiarrhythmic efficacy of procainamide." School of Pharmacy, University of Wisconsin, Madison, WI, December 13, 1995. 6. "A tale of crack'd hearts: Cardiovascular effects of cocaine." College of Pharmacy, University of Michigan, Ann Arbor, MI, September 10, 1997. 7. "A tale of crack'd hearts: Cardiovascular effects of cocaine." University of Michigan Substance Abuse Research Center, Ann Arbor, MI, September 10, 1997. 8. "A tale of quivering hearts: Culprits and mechanisms of drug-induced arrhythmias." Department of Biological Sciences, Bowling Green State University, Bowling Green, OH, November 6, 1998. 9. "A tale of quivering hearts: Culprits and mechanisms of drug-induced arrhythmias." Division of Pharmacotherapy, College of Pharmacy, University of Texas, San Antonio, TX, March 8, 2000. 10. “Pharmacotherapy of arrhythmias: focus on atrial fibrillation.” College of Pharmacy, University of Georgia, Medical College of Georgia, Augusta, GA, February 20, 2002. 11. “Pharmacotherapy of atrial fibrillation.” Cardiology Grand Rounds, Medical College of

Georgia, Augusta, GA, February 21, 2002. 12. “Pathophysiology and management of atrial fibrillation.” Misr International University,

Cairo, Egypt, May 8, 2005.


61

Presentations (Invited Professor) cont’d: 13. “Pathophysiology and management of heart failure.” Misr International University,

Cairo, Egypt, May 9, 2005. 14. “Pathophysiology and management of ischemic heart disease.” Misr International University, Cairo, Egypt, May 10, 2005. 15. “Pathophysiology and management of hyperlipidemia.” Misr International University,

Cairo, Egypt, May 11, 2005. 16. “Case discussion in atrial fibrillation.” Misr International University, Cairo, Egypt, May 12, 2005. 17. “Case discussion in heart failure.” Misr International University, Cairo, Egypt, May 15, 2005. 18. “Case discussion in hyperlipidemias.” Misr International University, Cairo, Egypt, May 18, 2005. 19. “Be still my palpitating heart: investigating the pharmacotherapy of atrial fibrillation and the problem of drug-induced arrhythmias.” Misr International University, Cairo, Egypt,

May 19, 2005. 20. “Pathophysiology and management of ischemic heart disease.” Misr International

University, Cairo, Egypt, May 2, 2006. 21. “Pathophysiology and management of heart failure.” Misr International University,

Cairo, Egypt, May 3, 2006. 22. “Pathophysiology of dysrhythmias.” Misr International University, Cairo, Egypt, May 4,

2006. 23. “Pathophysiology and management of atrial fibrillation.” Misr International University,

Cairo, Egypt, May 6, 2006. 24. “Case discussion in ischemic heart disease.” Misr International University, Cairo, Egypt, May 8, 2006. 25. “Case discussion in heart failure.” Misr International University, Cairo, Egypt, May 9, 2006.


62

Presentations (Invited Professor) cont’d: 26. “Case discussion in atrial fibrillation.” Misr International University, Cairo, Egypt, May 10, 2006. 27. “Pharmacy education and the pharmacy curriculum at Purdue University,” Misr

International University, Cairo, Egypt, May 11, 2006. 28. “Ex vivo and animal models in arrhythmia research.” Graduate seminar, Department of Pharmacy Practice, University of Iowa, Iowa City, IA, November 7, 2006. 29. “First do no harm: detection, prevention and management of drug-induced diseases.”

Faculty of Pharmacy, University of Manitoba, Winnipeg, Manitoba, Canada, January 26, 2007.

30. “A new model for experiential training of pharmacy students: longitudinal advanced

practice program (LAPP).” Presented to the Curriculum Committee of the Faculty of Pharmacy, University of Manitoba, Winnipeg, Manitoba, Canada, January 26, 2007.

31. “Post-PharmD fellowship training as a pathway to becoming a clinical scientist.” College

of Pharmacy, Ferris State University, Kalamazoo, MI, February 21, 2007. 32. “Clinical and applied research in cardiovascular pharmacotherapy at Purdue University:

opportunities for fellowship training." College of Pharmacy, Ferris State University, Big Rapids, MI, February 22, 2007.

33. “Adventures in arrhythmias: prevention and management of atrial fibrillation and drug-

induced arrhythmias.” College of Pharmacy, University of Florida, Gainesville, FL, January 18, 2008.

34. “Rhythm blues: understanding mechanisms and risk factors for drug-induced

arrhythmias.” School of Pharmacy, University of Wisconsin, Madison, WI, January 29, 2010.

35. “Rhythm blues: understanding mechanisms and risk factors for drug-induced

arrhythmias.” School of Pharmacy, University of Southern California, Los Angeles, CA, February 23, 2010.

36. “Training future pharmacist-researchers and practitioners,” Faculty of Pharmacy,

University of Toronto, Toronto, Ontario, Canada, February 6, 2012.


63

Presentations (Invited Professor) cont’d: 37. “Reducing the risk of drug-induced QT interval prolongation.” Faculty of Pharmacy,

University of Manitoba, Winnipeg, Manitoba, Canada, September 24, 2014. 38. “First do no harm: prevention, detection and management of drug-induced diseases.”

Medicine Grand Rounds, Faculty of Medicine, University of Alberta, Edmonton, Alberta, Canada, June 5, 2015.

39. “Reducing the risk of drug-induced QT interval prolongation.” Faculty of Pharmacy,

University of Alberta, Edmonton, Alberta, Canada, June 5, 2015. 40. “Drug-induced QT interval prolongation and torsades de pointes: strategies for risk

assessment and prevention.” Medicine Grand Rounds, Dalhousie University, Halifax, Nova Scotia, Canada, September 29, 2015.

Other presentations: 1. Commencement address, College of Pharmacy & Health Sciences, Wayne State

University, Detroit, MI, May 5, 2010. 2. Commencement address, Pharmacy Residency Program, Medical University of South

Carolina (MUSC) Medical Center & South Carolina College of Pharmacy at MUSC, Charleston, SC, June 30, 2010.

3. Commencement address, American College of Clinical Pharmacy Academy Graduation

Ceremony, Albuquerque, NM, October 15, 2013. 4. “Drug-induced QT interval prolongation and torsades de pointes: strategies for risk

assessment and prevention.” Medicine Grand Rounds, School of Medicine, Indiana University, Indianapolis, IN, October 23, 2015.

5. “Influence of progesterone administration on drug-induced torsades de pointes in AV

node-ablated isolated perfused rabbit hearts.” Presented as an Encore Presentation poster at the Annual Meeting of the American College of Clinical Pharmacy, Hollywood, FL, October 24, 2016.

6. Webinar entitled “Emergent Management of Arrhythmias,” coordinated jointly with the

American College of Clinical Pharmacy Cardiology and Emergency Medicine Practice and Research Networks. Co-presented with Drs. Nicole Gasbarro and Darrel Hughes, September 7, 2017.


64

Other presentations (cont’d): 7. “Intravenous amiodarone for prevention of atrial fibrillation following esophagectomy: a

propensity score-matched analysis.” Presented as an Encore Presentation poster at the Annual Meeting of the American College of Clinical Pharmacy, Phoenix, AZ, October 9, 2017.

James Tisdale CV - Purdue University · CURRICULUM VITAE James Edward Tisdale Business Address:...

Documents

Transcript of James Tisdale CV - Purdue University · CURRICULUM VITAE James Edward Tisdale Business Address:...